<SEC-DOCUMENT>0001178913-21-002924.txt : 20210903
<SEC-HEADER>0001178913-21-002924.hdr.sgml : 20210903
<ACCEPTANCE-DATETIME>20210903160417
ACCESSION NUMBER:		0001178913-21-002924
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20210903
FILED AS OF DATE:		20210903
DATE AS OF CHANGE:		20210903

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813676773
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		211236461

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>zk2126532.htm
<DESCRIPTION>PRE 14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 7.5.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div id="DSPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-size: 14pt;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SCHEDULE 14A</div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Filed by the Registrant <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Filed by a Party other than the Registrant <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Check the appropriate box:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160;&#160; Preliminary Proxy Statement</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#160;&#160;&#160; Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#160;&#160;&#160; Definitive Proxy Statement</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#160;&#160;&#160; Definitive Additional Materials</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#160;&#160;&#160; Soliciting Material Pursuant to &#167;240.14a-12</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-size: 16pt;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
        <div>Chemomab Therapeutics Ltd.</div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Name of Registrant as Specified In Its </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Charter)</div>
    <div style="line-height: 1.25;">&#160;
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Name of Person(s) Filing Proxy Statement, if </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">other than the Registrant)</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Payment of Filing Fee (Check the appropriate box):</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160;&#160; No fee required.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#160;&#160;&#160; Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zadceed893f5046f7b1e1db4c1302eb0b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Title of each class of securities to which transaction applies:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 3%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 97%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z7d1ebd1d6eaf4157b173ba6da0455161" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Aggregate number of securities to which transaction applies:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 3%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 97%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="zdec1aa80b68c4639a09575906129b316" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">3)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 3%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 97%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="zce94ce67d7724b9fb4f33b61df1ef112" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">4)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Proposed maximum aggregate value of transaction:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 3%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 97%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z56105218dc5c4dac9e378b4e43f708c2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">5)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Total fee paid:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 3%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 97%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
    <div style="line-height: 1.25;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#160;&#160;&#160; Fee paid previously with preliminary materials:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;"><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#160;&#160;&#160; Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid
      previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z57a04105820a46609b29380b33e2fd20" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Amount Previously Paid:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 3%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 97%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z1b6e57099b274e38ade40c1eefb7c718" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Form, Schedule or Registration Statement No.:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 3%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 97%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="ze50ac5751c174b54aaca55f73d3d3b99" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">3)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Filing Party:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 3%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 97%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="zf861880af564472db9013663157cdfb7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">4)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Date Filed:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zccc757405d8b4a6ab5f739e28dc4e1b9">

          <tr>
            <td style="width: 3%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 97%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><img width="175" height="98" src="image9.jpg"></div>
    <div style="line-height: 1.25;">[&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ], 2021</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Dear Shareholder,</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">You are cordially invited to attend a special meeting of the shareholders (the &#8220;Special Meeting&#8221;) of Chemomab Therapeutics Ltd. (&#8220;we,&#8221; &#8220;Chemomab,&#8221; the &#8220;Company&#8221; or &#8220;our company&#8221;) to be held at 4:30
      p.m., local time, on October 25, 2021, at Meitar | Law Offices, located at 16 Abba Hillel Road, 10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> floor, Ramat Gan 5250608, Israel.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">At the Special Meeting, shareholders will vote on the matters listed in the enclosed Notice of Special General Meeting of Shareholders. We look forward to greeting personally those shareholders who are
      able to be present at the Special Meeting; however, whether or not you plan to attend in person, it is important that your shares be represented. Holders of our American Depositary Shares (&#8220;ADSs&#8221;) will receive voting instruction cards either
      electronically or by physical mail, depending on the delivery instructions such holder has provided to its bank or broker. Please promptly vote your shares by marking, signing, dating and returning the voting instruction card in the enclosed envelope
      or by submitting your voting instructions online or by phone (if permitted to do so, as described in the voting instruction card that you receive).</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Your vote is important, whether or not you attend the meeting in person. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting. If you decide to attend the
      meeting and vote in person, your proxy may be revoked at your request.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Thank you for your cooperation and continued support.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Sincerely,</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;"><u>/s/ Stephen Squinto</u><br>
      Stephen Squinto<br>
      Chairman of the Board</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25;"><img width="254" height="143" src="image10.jpg"></div>
    <div style="text-align: center; line-height: 1.25;">&#160;<u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">NOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS<br>
      TO BE HELD ON OCTOBER 25, 2021</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">To the Shareholders of Chemomab Therapeutics Ltd.:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The Special General Meeting of Shareholders of Chemomab Therapeutics Ltd. will be held at the following time, date and place for the following purpose:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="zbf97cebba0e84e989463bd4476e0e8d3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 6%; vertical-align: top;">
            <div style="line-height: 1.25;">TIME:</div>
          </td>
          <td style="width: 94%; vertical-align: top;">
            <div style="line-height: 1.25;">4:30 p.m. local time</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 94%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;">
            <div style="line-height: 1.25;">DATE:</div>
          </td>
          <td style="width: 94%; vertical-align: top;">
            <div style="line-height: 1.25;">October 25, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 94%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;">
            <div style="line-height: 1.25;">PLACE:</div>
          </td>
          <td style="width: 94%; vertical-align: top;">
            <div style="line-height: 1.25;">Meitar | Law Offices, located at 16 Abba Hillel Road, 10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> floor, Ramat Gan 5250608, Israel</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 94%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;">
            <div style="line-height: 1.25;">PURPOSE:</div>
          </td>
          <td style="width: 94%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">The agenda for the Special General Meeting is as follows:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zc56da8ea3ef6485d983a193cfb51432b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 54pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Approval of the terms of employment of Dr. Dale Pfost, who was engaged as the Chief Executive Officer of the Company on [&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ], 2021.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The foregoing proposal is described more fully in the enclosed proxy statement, which we urge you to read in its entirety.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the voting power represented at the Special Meeting in person or by proxy and voting thereon is necessary for the approval of the proposal.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Additionally, the approval of the proposal is subject to the fulfillment of one of the following additional voting requirements:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z3ed4065ef4ec44b4b0df3bf5abc9d5aa" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">(i)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>approval by a majority of the ordinary shares or ADSs held and voted at the Special Meeting by non-controlling shareholders who do not have a conflict of interest (referred to under the Israeli Companies Law, 5759-1999 (the &#8220;Companies Law)
              as a &#8220;personal interest&#8221;) in the approval of the proposal, excluding abstentions; or</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zaad3ff4490c241bfbdd84ef28a9e70f1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">(ii)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the total number of shares held by non-controlling, disinterested shareholders (as described in the previous bullet-point) and voted against the proposal, does not exceed two percent (2%) of the aggregate voting rights in the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In connection with the proposal, the Companies Law allows the board of directors of a company to approve such proposal even if the general meeting of shareholders has voted against its approval,
      provided that the company&#8217;s compensation committee, and thereafter its board of directors, each determines to approve it, based on detailed arguments, and after having reconsidered the matter and concluded that such action is in the best interest of
      the company.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">A &#8220;controlling shareholder&#8221; is defined as any shareholder that has the ability to direct the company&#8217;s activities (other than by means of being a director or other office holder (as defined in the
      Companies Law) of the company). Two or more persons holding voting rights in the company, each of whom has a personal interest in the approval of the transaction being brought for approval of the company, will be considered to be joint holders. A
      person is presumed to be a controlling shareholder if he, she or it holds or controls, by himself, herself or itself, or together with others, one-half or more of any one of the &#8220;means of control&#8221; of the company. For certain matters, including with
      respect to the proposal at the Special Meeting, a person who holds 25% or more of the voting rights in the general meeting of the company will be deemed a controlling shareholder if there is no other person who holds more than 50% of the voting
      rights in the company. &#8220;Means of control&#8221; is defined as any one of the following: (i) the right to vote at a general meeting of the company, or (ii) the right to appoint directors of the company or its chief executive officer.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">A &#8220;personal interest&#8221; of a shareholder in an action or transaction of a company includes (i) a personal interest of any of the shareholder&#8217;s relative (i.e. spouse, brother or sister, parent,
      grandparent, child as well as child, brother, sister or parent of such shareholder&#8217;s spouse or the spouse of any of the above) or an interest of a company with respect to which the shareholder or the shareholder&#8217;s relative (as detailed above) holds
      5% or more of such company&#8217;s issued shares or voting rights, in which any such person has the right to appoint a director or the chief executive officer or in which any such person serves as a director or the chief executive officer, including the
      personal interest of a person voting pursuant to a proxy whether or not the proxy grantor has a personal interest; and (ii) excludes an interest arising solely from the ownership of ordinary shares or ADSs of the company.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Shareholders of record at the close of business on October 1, 2021 are entitled to vote at the Special Meeting. A list of shareholders of record will be available at the Special Meeting and, during the
      10 days prior to the Special Meeting, at the office of our Corporate Secretary at our registered office in Israel, Kiryat Atidim, Building 7, Tel Aviv, 6158002, Israel.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 21.6pt; line-height: 1.25; font-weight: bold;">Please sign, date and promptly return the enclosed voting instruction card or proxy card in the enclosed envelope or submit your voting instructions online or by phone (if
      permitted to do so, as described in the voting instruction card that you receive) so that your shares will be represented whether or not you attend the Special Meeting.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z62b689e3eb2c426ba14a549ca8751d32" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">BY ORDER OF THE BOARD OF DIRECTORS</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;"><u>/s/ Stephen Squinto</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Stephen Squinto</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Chairman of the Board</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">[&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; ], 2021</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">- ii -</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.<br>
      Kiryat Atidim, Building 7<br>
      Tel Aviv, Israel 6158002<br>
      +972-77-331-0156</div>
    <div style="text-align: center; line-height: 1.25;"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROXY STATEMENT FOR CHEMOMAB THERAPEUTICS LTD.<br>
      SPECIAL GENERAL MEETING OF SHAREHOLDERS<br>
      TO BE HELD ON OCTOBER 25, 2021</div>
    <div style="text-align: center; line-height: 1.25;">&#160;<u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">GENERAL INFORMATION ABOUT THE SPECIAL MEETING</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Why Did You Send Me this Proxy Statement?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We sent you this proxy statement and the enclosed proxy card because the board of directors of Chemomab Therapeutics Ltd. (&#8220;we,&#8221; the &#8220;Company,&#8221; &#8220;our company&#8221; or &#8220;Chemomab&#8221;) is soliciting your proxy to
      vote at the Special General Meeting of Shareholders (the &#8220;Special Meeting&#8221;) and any adjournments of the Special Meeting to be held at 4:30 p.m., local time, on October 25, 2021 at Meitar | Law Offices, located at 16 Abba Hillel Road, 10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>
      floor, Ramat Gan 5250608, Israel. This proxy statement, along with the accompanying Notice of Special General Meeting of Shareholders, summarizes the purpose of the Special Meeting and the information you need to know to vote at the Special Meeting.
      We anticipate that on or about [&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; ], 2021, we will begin sending this proxy statement, the attached Notice of Special Meeting and the form of proxy enclosed to all shareholders entitled to vote at the Special Meeting.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Who Can Vote?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Only holders of record of ordinary shares or ADSs representing the Company&#8217;s ordinary shares (collectively, the &#8220;Shares&#8221;) on October 1, 2021 (the &#8220;record date&#8221;) are entitled to vote at the Special
      Meeting. On the record date, there were [&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ] ordinary shares (equivalent to [&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; ] ADSs) outstanding and entitled to vote.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">You do not need to attend the Special Meeting to vote your Shares. Shares represented by valid proxies, received in time for the Special Meeting and not revoked prior to the Special Meeting, will be
      voted at the Special Meeting.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">How Many Votes Do I Have?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Each ordinary share that you own entitles you to one vote. Each ADS represents twenty (20) of our ordinary shares.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">How Do I Vote?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Whether you plan to attend the Special Meeting or not, we urge you to vote by proxy. Voting by proxy will not affect your right to attend the Special Meeting. If your Shares are registered directly in
      your name through our transfer agent, or you have share certificates, you may vote:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb88b6c86b18a4ce4a6164c807d65ae48" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">By mail. </font>Complete, date, sign and mail the enclosed proxy card in the enclosed postage prepaid envelope. Your proxy will be voted in accordance with your instructions. If you sign the proxy card but
              do not specify how you want your Shares voted, they will be voted as recommended by our board of directors.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zfb952dc0c4d54a999c68ae91cab59e6b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">In person at the meeting. </font>If you attend the Special Meeting, you may deliver your completed proxy card in person or you may vote by completing a ballot, which will be available at the Special
              Meeting.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-indent: 36pt; line-height: 1.25;">If your ADSs are held in &#8220;street name&#8221; (held in the name of a bank, broker or other nominee), you must provide the bank, broker or other nominee with instructions on how to vote your Shares and can
      generally do so as follows:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zd6bc1148215747c3ad5a811d17e19f76" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">By mail. </font>You will receive instructions from your broker or other nominee explaining how to instruct them to vote your Shares.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z13ea8a489d4a4f83b6b24749f5cd7417" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;">By Phone and/or Online.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb633afb7efeb4f839c1bf4aa0b5ce7f4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 51.75pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-style: italic;">Beneficial Holders</font> can complete and submit voting instructions online at www.ProxyVote.com, in accordance with the instructions provided on the voting instruction card that you receive, or by
              calling 1-800-454-8683.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zf060a08141d04bd689e5af4891dc3324" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 51.75pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-style: italic;">Registered Holders</font> can complete and submit voting instructions online at www.proxypush.com/CMMB in accordance with the instructions on the voting instruction card you receive.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zdbb95393acc144f58dd11534b1829ca0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">In person at the Special Meeting. </font>Contact the broker or other nominee who holds your Shares to obtain a broker&#8217;s proxy card and bring it with you to the Special Meeting. You will not be able to vote
              at the Special Meeting unless you have a proxy card from your broker.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">What am I Voting On?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">You are voting on:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="za3b4cbbbc4de42d3846fb22c3f55d13e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the approval of the terms of employment of Dr. Dale Pfost, who was engaged as the Chief Executive Officer of the Company on [&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ], 2021</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Our board of directors reserves the right to elect not to proceed with and to abandon the foregoing proposal if it determines, in its sole discretion, that the proposal is no longer in the best
      interests of the shareholders.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">How does the Board of Directors Recommend that I Vote at the Special Meeting?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">The board of directors recommends that you vote as follows:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="ze3940c580e964d39854dae5e1d69962d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;<font style="font-weight: bold;">FOR</font>&#8221; the proposal to approve the terms of employment of Dr. Dale Pfost, who was engaged as the Chief Executive Officer of the Company on [&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ], 2021</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If any other matter is properly presented at the Special Meeting or any adjournment, the proxy card provides that your Shares will be voted by the proxy holder listed on the proxy card in accordance
      with his or her best judgment. At the time this proxy statement was printed, we knew of no matters that needed to be acted on at the Special Meeting, other than those discussed in this proxy statement.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">What Constitutes a Quorum for the Special Meeting?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Due to the Nasdaq listing rules applicable to our Company, of the [&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ] ordinary shares outstanding as of the record date, the holders of at least 33&#160;1/3% of those ordinary shares, or
      at least [&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ] ordinary shares, must be present at the meeting in person or represented by proxy to hold the meeting and conduct business. Once a quorum is established at a meeting, it shall not be broken by the withdrawal of enough
      votes to leave less than a quorum. Shares held by shareholders of record who are present at the meeting in person or by proxy are counted for purposes of determining whether a quorum exists. Abstentions and &#8220;broker non-votes&#8221; are also counted as
      present and entitled to vote for purposes of determining whether a quorum exists. If a quorum is not present, the meeting will be adjourned until a quorum is obtained.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">What are the Voting Requirements to Approve the Proposals?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">You may vote &#8220;FOR,&#8221; &#8220;AGAINST&#8221; or &#8220;ABSTAIN&#8221; on the proposal to approve the terms of employment of Dr. Dale Pfost, who was engaged as the Chief Executive Officer of the Company on [&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ],
      2021.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The affirmative vote of a majority of our ordinary shares or ADSs present at the Special Meeting, in person or by proxy, and voting on the matter, is required to approve the proposal described above, <font style="font-style: italic;">provided that</font>, in addition to such majority vote, either (i) a majority of the shares of shareholders present and voting who are not controlling shareholders and do not have a conflict of interest (referred to as
      a &#8220;personal interest&#8221; under the Israeli Companies Law 5759-1999 (the &#8220;Companies Law&#8221;)) in the approval of the proposal, excluding abstentions, are voted in favor of the proposal; or (ii) the total number of shares held by the shareholders mentioned
      in clause (i) above that are voted against the proposal does not exceed two percent (2%) of the aggregate voting rights in the Company.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">A &#8220;controlling shareholder&#8221; is defined as any shareholder that has the ability to direct the company&#8217;s activities (other than by means of being a director or other office holder (as defined in the
      Companies Law) of the company. Two or more persons holding voting rights in the company each of which has a personal interest in the approval of the transaction being brought for approval of the company will be considered to be joint holders. A
      person is presumed to be a controlling shareholder if it holds or controls, by himself or together with others, one half or more of any one of the &#8220;means of control&#8221; of the company, although for certain matters, including with respect to Proposal 1,
      a person who holds 25% or more of the voting rights in the general meeting of the company if there is no other person who holds more than 50% of the voting rights in the company will be deemed a controlling shareholder &#8220;Means of control&#8221; is defined
      as any one of the following: (i) the right to vote at a general meeting of the company, or (ii) the right to appoint directors of the company or its chief executive officer.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">A &#8220;personal interest&#8221; of a shareholder in an action or transaction of a company includes (i) a personal interest of any of the shareholder&#8217;s relative (i.e. spouse, brother or sister, parent,
      grandparent, child as well as child, brother, sister or parent of such shareholder&#8217;s spouse or the spouse of any of the above) or an interest of a company with respect to which the shareholder or the shareholder&#8217;s relative (as detailed above) holds
      5% or more of such company&#8217;s issued shares or voting rights, in which any such person has the right to appoint a director or the chief executive officer or in which any such person serves as a director or the chief executive officer, including the
      personal interest of a person voting pursuant to a proxy whether or not the proxy grantor has a personal interest; and (ii) excludes an interest arising solely from the ownership of ordinary shares or ADSs of the company.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The Companies Law requires that each shareholder voting on the proposed resolution indicate whether or not the shareholder is a controlling shareholder or has a personal interest in the proposed
      resolution. Otherwise, the votes of such shareholder will not be counted.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">The proxy card or voting instruction card includes Item 1A, under which you should mark &#8220;YES&#8221; in order to confirm that you are <font style="font-weight: bold;"><u>not</u></font> a controlling
      shareholder and do <font style="font-weight: bold;"><u>not</u></font> have a personal interest in the approval of the proposal. In the alternative, if you believe that you are a controlling shareholder or have such a personal interest in the
      approval of the proposal, you should mark the box &#8220;NO&#8221; in Item 1A when you mark your vote with respect to the proposal. <font style="font-weight: bold;">If you do not mark any box in Item 1A, your vote will not be counted on the proposal.</font> If
      you are unsure whether you are a controlling shareholder or have a personal interest in the proposal, please contact the Company&#8217;s Chief Financial Officer, Sigal Fattal, at <u>sigal@chemomab.com</u>, or, if you hold your ADSs in &#8220;street name,&#8221; you
      may also contact the representative managing your account, who would then contact us on your behalf.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">How are My Votes Cast when I Sign and Return a Voting Instruction Card or Proxy Card?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">When you sign and submit a voting instruction card, you instruct your broker (or nominee that holds your ADSs of record) to vote your ADSs in a certain manner. When you sign a proxy card, you appoint
      Dr. Adi Mor, our outgoing Chief Executive Officer and who will continue to serve as our Chief Scientific Officer and as a director of our Company upon the commencement of Dr. Pfost&#8217;s service, and Sigal Fattal, our Chief Financial Officer, as your
      representatives at the Special Meeting. Your broker (or other nominee), in the case of ADSs held in street name, or Dr. Mor and Ms. Fattal, in the case of Shares held by record shareholders, will ensure that your Shares are voted at the Special
      Meeting as you have instructed them on the voting instruction card or proxy card (as applicable). Each of such persons may appoint a substitute for himself.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Even if you plan to attend the Special Meeting, it is a good idea to complete, sign and return your voting instruction card or proxy card in advance of the Special Meeting in case your plans change.
      This way, your Shares will be voted by you whether or not you actually attend the Special Meeting.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">May I Revoke My Proxy?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Shareholders may revoke the authority granted by their execution of proxies before the effective exercise thereof by filing with the Company a written notice of revocation or duly executed proxy
      bearing a later date, or by voting in person at the Special Meeting. However, if a shareholder attends the Special Meeting and does not elect to vote in person, his or her proxy will not be revoked. Unless otherwise indicated on the form of proxy, if
      a proxy is properly executed and received by the Company prior to the Special Meeting, Shares represented by the proxy will be voted in favor of the matter to be presented to the Special Meeting, as described above.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Can my broker vote my Shares for me?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">A broker &#8220;non-vote&#8221; occurs when a broker or nominee holding Shares for a beneficial owner does not vote on a particular matter because the matter is not routine and such broker or nominee does not have
      the discretionary voting authority to vote the Shares for which it is the holder of record with respect to a particular matter at the Special Meeting and such broker or nominee has not received instructions from the beneficial owner. Broker
      &#8220;non-votes,&#8221; and Shares as to which proxy authority has been withheld with respect to any matter, are generally not deemed to be entitled to vote for purposes of determining whether a majority of the shareholders have voted in favor of a particular
      proposal.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">What if I Receive More than One Proxy Card?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">You may receive more than one proxy card or voting instruction form if you hold Shares in more than one account, which may be in registered form or held in street name. Please vote in the manner
      described under &#8220;How Do I Vote?&#8221; for each account to ensure that all of your Shares are voted.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">What if I do not Vote for the Matters Listed on My Proxy Card?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">On all matters considered at the Special Meeting, abstentions of a holder of Shares will be treated as neither a vote &#8220;for&#8221; nor a vote &#8220;against&#8221; the matter, although they will be counted in determining
      if a quorum is present.&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Will My Shares be Voted if I do not Return My Proxy Card and do not Attend the Special Meeting?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If your Shares are registered in your name or if you have share certificates, they will not be voted if you do not return your proxy card by mail or vote at the meeting as described above under &#8220;How Do
      I Vote?&#8221;.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">If your Shares are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your Shares as described above under &#8220;How Do I Vote?,&#8221; the bank, broker
      or other nominee has the authority to vote your Shares on certain routine matters scheduled to come before the meeting even if it does not receive instructions from you. We encourage you to provide voting instructions. This ensures your Shares will
      be voted at the meeting in the manner you desire.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Is Voting Confidential?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Yes. Only the inspector of elections and our employees who have been assigned the responsibility for overseeing the legal aspects of the Special Meeting, will have access to your proxy card. The
      inspector of elections will tabulate and certify the vote. Any comments written on the proxy card will remain confidential unless you ask that your name be disclosed.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">What are the Costs of Soliciting these Proxies?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We will pay all of the costs of soliciting these proxies. Our officers, directors and employees may solicit proxies in person or by telephone, fax or email. We will pay these employees and directors no
      additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy materials to their principals and to obtain authority to execute proxies. We will then reimburse them for
      their expenses.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;
      <div style="line-height: 1.25; font-weight: bold;">Could other Matters be Decided at the Special Meeting?</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">We do not know of any other matters that will be considered at the Special Meeting. If any other matters arise at the Special Meeting at or by the direction of the board of directors, the proxies
        will be voted at the discretion of the proxy holders.</div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">What Happens if the Special Meeting is Postponed or Adjourned?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Your proxy will still be valid and may be voted at the postponed or adjourned meeting. You will still be able to change or revoke your proxy until it is voted.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">What are the Implications of the Company being an Emerging Growth Company and a Smaller Reporting Company?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) and a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 under the Securities
      Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). As an emerging growth company and a smaller reporting company, we provide in this proxy statement the scaled disclosure permitted under the JOBS Act and otherwise as applicable to smaller
      reporting companies. In addition, as an emerging growth company, we are not required to conduct votes seeking shareholder approval on an advisory basis of (1) the compensation of our &#8220;named executive officers&#8221; or the frequency with which such votes
      must be conducted or (2) compensation arrangements and understandings in connection with merger transactions, known as &#8220;golden parachute&#8221; arrangements.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPANY BACKGROUND</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Company Overview</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Chemomab is a clinical-stage biotech company discovering and developing innovative therapeutics for conditions with high unmet medical need that involve inflammation and
        fibrosis.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Chemomab has pioneered the therapeutic targeting of CCL24, a chemokine that promotes various types of cellular processes that regulate inflammatory and fibrotic activities
        through the CCR3 receptor. The chemokine is expressed in various types of cells, including immune cells, endothelial cells and epithelial cells. We have developed a novel CCL24 inhibiting product candidate with dual anti-fibrotic and
        anti-inflammatory activity that modulates the complex interplays of both of these inflammatory and fibrotic mechanisms that drive abnormal states of fibrosis and clinical fibrotic diseases. This innovative approach is being developed for difficult
        to treat rare diseases, also known as orphan indications or diseases, such as primary sclerosing cholangitis, or PSC and systemic sclerosis, or SSc, for which patients have no established disease modifying standard of care treatment options.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">CM-101, the Company&#8217;s lead clinical product candidate, is a first-in-class humanized monoclonal antibody that hinders the basic function of the soluble chemokine CCL24, also
        known as eotaxin-2, as a regulator of major inflammatory and fibrotic pathways. We have demonstrated that CM-101 interferes with the underlying biology of inflammation and fibrosis through a novel and differentiated mechanism of action. Based on
        these findings, Chemomab is actively advancing CM-101 into Phase 2 clinical studies directed toward three distinct clinical indications including patients with liver, skin, and/or lung fibrosis. We have completed two Phase 1a clinical studies at
        varying doses using different administration methods, as well as a Phase 1b safety, tolerability and proof-of-mechanism clinical study of CM-101 in non-alcoholic fatty liver disease, or NAFLD, patients. We are currently conducting a Phase 2a
        clinical study in PSC, a rare obstructive and cholestatic liver disease. The study is actively recruiting patients in the United Kingdom and Israel and is being expanded to additional territories with significant recruitment potential. In addition,
        we are planning a Phase 2 study in SSc, expected to initiate early next year, which is a rare autoimmune rheumatic disease characterized by accumulation of collagen, resulting in fibrosis in multiple tissues. Although our primary focus relates to
        these two rare indications, an additional Phase 2a clinical study is currently enrolling patients and is focused on expanding the understanding of CM-101 in non-alcoholic steatohepatitis, or NASH. This trial will provide important safety and PK
        data designed to support the development of CM-101 subcutaneous formulation.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Fibrosis is the abnormal and excessive accumulation of collagen and extracellular matrix, the non-cellular component in all tissues and organs, that provide structural and
        biochemical support to surrounding cells. When present in excessive amounts, collagen and extracellular matrix lead to scarring and thickening of connective tissues, affecting tissue properties and potentially leading to organ failure. Fibrosis can
        occur in many different tissues, including lung, liver, kidney, muscle, skin, and the gastrointestinal tract, resulting in a wide array of progressive fibrotic conditions. Fibrosis and inflammation are intrinsically linked. While a healthy
        inflammatory response is necessary for efficient tissue repair, after injury, an excessive, uncontrolled inflammatory response can lead to tissue fibrosis.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
    <div style="page-break-after: always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div><br>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS<br>
      AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The following table sets forth information, as of September 1, 2021, regarding beneficial ownership of our ordinary shares (including ordinary shares represented by ADSs):</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zf6c0d2ff282a47eeb9fe47a5d39cf5cd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>each person who is known by us to own beneficially more than 5% of our ordinary shares;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z122a27cbcd1348cebe62370e1c11e497" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>each director;</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z52aba5aeb6304f65becdb7907b4c5d99" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>each executive officer; and</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" id="z9a00f991266f45b9aaf325f35420a3d7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 20.25pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>all of our directors and executive officers collectively.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The percentages of ordinary shares beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC,
      a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or investment power, which includes the power to dispose of or to direct
      the disposition of the security.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Unless otherwise noted, the address of each director and current and former executive officer of Chemomab is Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z25bf6052204f4e9fb0d76a4356de598d">

        <tr>
          <td valign="bottom" style="vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Total</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Beneficial</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Percentage of</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Ownership</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Ordinary</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">(American</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Shares</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Depositary</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Beneficially</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">NAME OF BENEFICIAL OWNER</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Shares)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Owned*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25; font-weight: bold;">5% and Greater Shareholders</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">OrbiMed Israel Partners Limited Partnership(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">2,606,991</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">22.8</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">The Centillion Fund(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">661,370</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">5.8</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">Rivendell Investments 2017-9(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">1,131,563</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">9.9</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">Kobi George(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">1,313,005</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">11.4</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">Apeiron group(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">770,388</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">6.7</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z23103e63864a4634b1a72fb4ebcc549f">

        <tr>
          <td style="vertical-align: bottom; text-align: center;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Total</div>
          </td>
          <td nowrap="nowrap" style="text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; text-align: center;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Beneficial</div>
          </td>
          <td nowrap="nowrap" style="text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Percentage of</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; text-align: center;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Ownership</div>
          </td>
          <td nowrap="nowrap" style="text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Ordinary</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; text-align: center;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">(American</div>
          </td>
          <td nowrap="nowrap" style="text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Shares</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; text-align: center;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Depositary</div>
          </td>
          <td nowrap="nowrap" style="text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Beneficially</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">NAME OF BENEFICIAL OWNER</div>
          </td>
          <td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Shares)</div>
          </td>
          <td nowrap="nowrap" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;" colspan="1">&#160;</td>
          <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;" colspan="2">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Owned*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25; font-weight: bold;">Directors and Executive Officers</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">Adi Mor(6)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">1,313,005</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">11.4</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">Neil Cohen(7)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">5,005</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">0.04</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">Arnon Aharon(8)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">55,040</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">0.48</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">Stephen Squinto(9)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">124,249</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">1.08</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">Nissim Darvish(10)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">12,433</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">0.11</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">Joel Maryles (11)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">2,310</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">0.01</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">Alan Moses (12)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">2,310</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">0.01</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">Claude Nicaise (13)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">2,310</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">0.01</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">Sigal Fattal&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">&#8212;</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">&#8212;</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25; font-weight: bold;">All current executive officers and directors as a group (9 persons)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">1,516,662</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">12.96</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">* Percentage ownership based on 11,397,803 ADSs outstanding as of September 1, 2021.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">(1) Represents 2,578,174 ADSs, representing 51,563,480 ordinary shares, held by OrbiMed Israel Partners Limited Partnership, or OIP and 28,817 ADSs, representing 576,340 Ordinary Shares, issuable upon
      the exercise of warrants to purchase ADSs. The percentage is calculated based upon 11,397,803 ADSs outstanding, representing 227,956,060 Ordinary Shares, and giving effect to the additional 28,817 ADSs, representing 576,340 Ordinary Shares, that
      would be outstanding following the exercise of the warrants held by OIP. OIP is the shareholder of record. OrbiMed Israel BioFund GP Limited Partnership, or OrbiMed BioFund, is the general partner of OIP, and OrbiMed Israel GP Ltd., or OrbiMed Israel
      GP, is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP and as a result, may be deemed to
      have beneficial ownership over such securities. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits, each of
      whom disclaims beneficial ownership of the shares held by OIP. The address of OIP is 89 Medinat HaYehudim St., Build E, 11th Floor, Herzliya 46766 Israel.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">(2) The address of Centillion Fund, Inc. is 10 Manoel Street, Castries, Saint Lucia.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">(3) Represents 1,108,509 ADSs, representing 22,170,180 ordinary shares, held by Rivendell Investments 2017-9 LLC, or
        Rivendell, as reported by Rivendell on Schedule 13G filed with the SEC on March 26, 2021, and 23,054 ADSs, representing 461,080 Ordinary Shares, issuable upon the exercise of warrants to purchase ADSs. The percentage is calculated based upon
        11,397,803 ADSs outstanding, representing 227,956,060 Ordinary Shares, and giving effect to the additional 23,054 ADSs, representing 461,080 Ordinary Shares, that would be outstanding following the exercise of the warrants held by Rivendell.
        Rivendell is the shareholder of record. Peter Thiel is the beneficial owner of Rivendell and has sole voting and investment power over the securities held by Rivendell. The address of Rivendell is 1209 Orange Street, Wilmington, Delaware 19801.</div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">(4) Consists of (i) 514,495 ADSs owned directly by Dr. George, (ii) 649,550 ADSs owned by Dr. Adi Mor&#160;(Dr. George&#8217;s spouse), (iii) 33,725 options to purchase 33,725 ADSs of the Company issued directly
      to Dr. George, issuable upon the exercise of options, and (iv) 115,235 options to purchase 115,235 ADSs of the Company, issued to Dr. Mor, (Dr. George&#8217;s spouse).</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">(5) The Apeiron Group consists of (i) Apeiron SICAV Ltd. &#8211; Presight Capital Fund One, of which owns 438,993 ADSs, (ii) Apeiron Presight Capital Fund II, LP, of which owns 316,987 ADSs, and (iii)
      Apeiron Investment Group Ltd., of which owns 14,408 ADSs issuable upon the exercise of warrants. Each of Fabian Hansen and Christian Angermayer may be deemed to share voting and investment power with respect to the ADSs held by the Apeiron Group.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">(6) Includes (i) 649,550 ADSs owned directly by Dr. Mor, (ii) 514,495 ADSs owned by Dr. George, (Dr. Mor&#8217;s spouse), (iii) 115,235 ADSs&#160; issued to Dr. Mor, issuable upon the exercise of options, and
      (iv) 33,725 options to purchase 33,725 ADSs of the Company issued to Dr. George, (Dr. Mor&#8217;s spouse) issuable upon the exercise of options.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">(7) Includes 2,409 ADSs of the Company, and 2,596 ADSs of the Company issuable upon the exercise of options, as reported by Mr. Neil Cohen on Form 4 filed with the SEC on March 26, 2021 and April 21,
      2021.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">(8) Represents 55,040 ADSs of the Company issuable upon the exercise of options, as reported by Mr. Arnon Aharon on Form 3 filed with the SEC on March 25, 2021.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">(9) Includes 47,938 ADSs of the Company, and 76,311 ADSs of the Company issuable upon the exercise of options, as reported by Dr. Stephen Squinto on Form 3 filed with the SEC on March 25, 2021 and Form
      4 filed with the SEC on April 21, 2021.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">(10) Represents 12,433 ADSs of the Company issuable upon the exercise of options, as reported by Dr. Nissim Darvish on Form 3 filed with the SEC on March 25, 2021 and Form 4 filed with the SEC on April
      21, 2021.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">(11) Represents 2,310 ADSs of the Company issuable upon the exercise of options, as reported by Mr. Joel Maryles on Form 4 filed with the SEC on April 21, 2021.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">(12) Represents 2,310 ADSs of the Company issuable upon the exercise of options, as reported by Dr. Alan Moses on Form 4 filed with the SEC on April 21, 2021.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">(13) Represents 2,310 ADSs of the Company issuable upon the exercise of options, as reported by Dr. Claude Nicaise on Form 4 filed with the SEC on April 21, 2021.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXECUTIVE OFFICERS AND DIRECTORS</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The following table sets forth the names and ages of the current directors and executive officers:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z196210c03d314dc78287c83d30e6ed0a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 34.85%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-weight: bold;">Name</div>
          </td>
          <td style="width: 1.22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 14.85%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-weight: bold;">Age</div>
          </td>
          <td style="width: 1.22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47.86%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25; font-weight: bold;">Positions Held</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.85%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Stephen Squinto<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td style="width: 1.22%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 14.85%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">64</div>
          </td>
          <td style="width: 1.22%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47.86%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Chairman of the Board</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.85%; vertical-align: top;">
            <div style="line-height: 1.25;">Adi Mor*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td style="width: 1.22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 14.85%; vertical-align: top;">
            <div style="line-height: 1.25;">40</div>
          </td>
          <td style="width: 1.22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47.86%; vertical-align: top;">
            <div style="line-height: 1.25;">Outgoing Chief Executive Officer, Chief Scientific Officer and Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.85%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Nissim Darvish<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td style="width: 1.22%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 14.85%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">56</div>
          </td>
          <td style="width: 1.22%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47.86%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.85%; vertical-align: top;">
            <div style="line-height: 1.25;">Joel Maryles<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td style="width: 1.22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 14.85%; vertical-align: top;">
            <div style="line-height: 1.25;">61</div>
          </td>
          <td style="width: 1.22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47.86%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.85%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Alan Moses<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td style="width: 1.22%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 14.85%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">73</div>
          </td>
          <td style="width: 1.22%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47.86%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.85%; vertical-align: top;">
            <div style="line-height: 1.25;">Claude Nicaise<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td style="width: 1.22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 14.85%; vertical-align: top;">
            <div style="line-height: 1.25;">68</div>
          </td>
          <td style="width: 1.22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47.86%; vertical-align: top;">
            <div style="line-height: 1.25;">Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.85%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Neil Cohen<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td style="width: 1.22%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 14.85%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">57</div>
          </td>
          <td style="width: 1.22%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47.86%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.85%; vertical-align: top;">
            <div style="line-height: 1.25;">Arnon Aharon*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td style="width: 1.22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 14.85%; vertical-align: top;">
            <div style="line-height: 1.25;">52</div>
          </td>
          <td style="width: 1.22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47.86%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Medical Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 34.85%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Sigal Fattal*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td style="width: 1.22%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 14.85%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">50</div>
          </td>
          <td style="width: 1.22%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47.86%; vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25;">Chief Financial Officer</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">*</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Officer</div>
    <div style="line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Independent Director</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Stephen Squinto, Ph.D.</font> has served on our board of directors as chairman since March 16, 2021. Dr. Squinto is a Partner at OrbiMed Advisors
      LLC, an investment firm, and has also served as acting Head of Research and Development of SpringWorks Therapeutics, Inc. Dr. Squinto currently serves on the boards of directors of Compass Therapeutics Inc., SpringWorks Therapeutics, Inc., VectivBio
      Holding AG, and several private companies. Dr. Squinto also previously served on the boards of directors of 89Bio, Inc., Arvinas, Inc., Audentes Therapeutics, Inc., Gemini Therapeutics Inc., and Passage Bio Inc. Previously, Dr. Squinto co-founded
      Alexion Pharmaceuticals, a biotechnology company, and served as its Executive Vice President and Chief Global Operations Officer from 2012 to January 2015 and as its Global Head of Research and Development from 2007 to 2012. Dr. Squinto holds a Ph.D.
      in biochemistry and biophysics and a B.A. in chemistry from Loyola University of Chicago. We believe Dr. Squinto is qualified to serve as a director due to his extensive experience as an entrepreneur and investor in the life sciences industry and his
      service on the boards of other public and private biopharmaceutical and biotechnology companies.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Adi Mor, Ph.D.</font> is the co-founder of Chemomab Ltd. and served as Chemomab Ltd.&#8217;s Chief Executive Officer, Chief Scientific Officer and a
      member of Chemomab Ltd.&#8217;s board of directors from its formation in 2011 until the Chemomab Ltd.-Anchiano Therapeutics Ltd. merger that was consummated on March 16, 2021 (the &#8220;Merger&#8221;), and has continued to serve in those capacities for our company
      following the Merger. In the event that the terms of employment of Dr. Pfost are approved at the Meeting, Dr. Mor will continue to serve as our Chief Scientific Officer and as a director of our Company. Dr. Mor has in-depth knowledge in immunology
      focusing on rare diseases and broad experience in designing, developing and patenting a novel class of monoclonal antibodies to treat inflammatory and fibrotic diseases. Dr. Mor received her Ph.D. in immunology from Tel Aviv University in the
      Department of Neurobiochemistry in Israel and is the lead author of numerous scientific journal publications in immunology and inflammatory disorders.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Nissim Darvish, M.D., Ph.D.</font> has served on our board of directors since March 16, 2021. Dr. Darvish is a Venture Partner at OrbiMed Israel, an
      investment firm. Dr. Darvish currently serves as a director of several private companies. Dr. Darvish previously served as a member of the boards of directors of 9 Meters Biopharma Inc. and Medigus Ltd. Previously, Dr. Darvish was employed at Pitango
      Venture Capital, where he was a General Partner managing life sciences investments. He was also the founder and CEO of Impulse Dynamics, where he culminated in a $250 million realization event. Dr. Darvish obtained his M.D. and Ph.D. in Biophysics
      and Physiology from the Technion in Israel, and subsequently conducted his post-doctoral research at NIH. He has published over 100 patents and authored over 20 publications. We believe that Dr. Darvish is qualified to serve on our board of directors
      based on his roles on several public and private boards of directors as well as his extensive experience in investing in healthcare companies.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Joel Maryles</font> has served on our board of directors since March 16, 2021. Mr. Maryles currently serves on the board of directors and as the
      Chairman of Remuneration Committee of Jefferies International Ltd., since 2016. Mr. Maryles previously served on the board of directors of Radware Ltd. (NASDAQ: RDWR), from 2014 to 2020 and from 2014 to 2016, on the board of directors of EZchip
      Semiconductor Ltd., which was acquired by Mellanox Technologies in 2016. From 2015 to 2018, Mr. Maryles was a Partner at OurCrowd and from 2007 to 2012, he served as a Portfolio Manager at T-Cubed Investments, which he founded. Prior to that, Mr.
      Maryles served as a Managing Director in the Investment Banking division of Citigroup, Israel and of Furman Selz. Mr. Maryles holds a Bachelor of Science in Mechanical Engineering from the University of Illinois and an MBA from the University of
      Chicago, Illinois.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Alan Moses, MD, FACP</font> has served on our board of directors since March 16, 2021. Dr. Moses is board certified by the ABIM with subspecialty
      certification in Endocrinology and Metabolism and is a Fellow of the American College of Physicians. Dr. Moses currently serves on the board of directors of BioFabUSA, since 2018. Prior to that time, from 2008 to 2018, Dr. Moses served as the Global
      Chief Medical Officer of Novo Nordisk A/S (CPH: NOVO-B), which he joined in 2004. Dr. Moses served as a Professor of Medicine at Harvard Medical School from 2002 to 2006, and in collaboration with MIT, he co-founded and co-directed the Clinical
      Investigator Training Program, which focused on training physician-scientists in translational research. Dr. Moses previously served as the Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center, from 1998 to 2004. Dr. Moses
      holds a BS from Duke University, North Carolina and an MD from Washington University School of Medicine, Missouri.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Claude Nicaise, MD</font> has served on our board of directors since March 16, 2021. Dr. Nicaise is a physician with extensive US and international
      experience in clinical drug development, strategic management, worldwide regulatory strategy, pharmaceuticals, biotechnology, including clinical cancer research, infectious diseases and neuroscience. Dr. Nicaise is the owner and founder of Clinical
      Regulatory Services, which provides consulting services to the life science and biotechnology industry in support of all aspects of clinical and regulatory development. Dr. Nicaise currently serves on the board of directors and as the Chairman of the
      Compensation Committee of Sarepta Therapeutics, Inc. (NASDAQ: SRPT), since 2015, as well as on the board of directors of Mynoryx Therapeutics, since 2017. Prior to that time, from 2008 to 2014, Dr. Nicaise served as the Senior Vice President of
      Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), and between 1984 and 2008, he held numerous senior management roles at Bristol Myers Squibb (NYSE: BMY). Dr. Nicaise holds an MD and a degree in Internal Medicine, Clinical Oncology, from Brussels
      University, Belgium.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Neil Cohen</font> has served as a member of our (formerly known as Anchiano Therapeutics Ltd.) board of directors since April 2020 and served as our
      interim Chief Executive Officer from October 2020 until the consummation of the Merger. Mr. Cohen has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since January 2012. In 1994, he co-founded Israel Seed Partners, a
      leading venture capital firm, and managed the firm until 2019. Mr. Cohen has invested in and served on the boards of directors of many private technology companies, including a large number which were acquired or completed successful initial public
      offerings, including Compugen (Nasdaq: CGEN), Shopping.com (Nasdaq: SHOP, acquired by EBAY), Broadlight (acquired by Broadcom, Nasdaq: AVGO) and Cyota (acquired by RSA). He is a venture partner at SKY, an Israeli middle-market private equity firm,
      Hetz Ventures Management Ltd., an early-stage Israeli venture capital fund, and Shavit Capital. Mr. Cohen was previously the Business Editor of The Jerusalem Post and began his career in the private equity group at N M Rothschild &amp; Sons Limited
      in London. Mr. Cohen received a B.A. and M.A. in Oriental Studies, with first class honors, from Oxford University.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Arnon Aharon, M.D. </font>served as Chemomab Ltd.&#8217;s Chief Medical Officer from January 2018 until the Merger and has continued in that capacity for
      our company following the Merger. Prior to his promotion, Dr. Aharon served as Chemomab&#8217;s Head of Clinical Development from December 2016 to December 2017. Prior to joining Chemomab, from January 2014 to November 2016, Dr. Aharon served as Chief
      Medical Officer at BioLineRx Ltd., a company listed on Nasdaq and The Tel Aviv Stock Exchange, where he directed the oncology and immunology pipeline. Dr. Aharon also served at multiple senior management positions at biotechnology companies,
      including Pharmos Ltd., a company listed on Nasdaq and The Tel Aviv Stock Exchange, Thrombotech Ltd., and LycoRed Ltd. Dr. Aharon is a member of several industry advisory groups and provides consulting services to biotechnology companies and academic
      institutions. Dr. Aharon received his M.D. from the University of Tel Aviv in Israel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Sigal Fattal</font> served as Chemomab Ltd.&#8217;s interim Chief Financial Officer from October 2020 until the Merger and has continued in that capacity
      for our company following the Merger. Prior to joining Chemomab Ltd., from March 2017 to December 2019, Ms. Fattal served as Chief Financial Officer at BiomX (NYSE American: PHGE), a clinical stage microbiome product discovery company. Prior to
      joining BiomX, Ms. Fattal served as Chief Financial Officer at Evogene (Nasdaq and TASE: EVGN), a computational biology company, from 2013 to 2016. Prior to that time, Ms. Fattal served in multiple financial and operational executive roles in various
      companies. Ms. Fattal also currently serves as co-founder of Simbiz, which was started in September 2020 and which offers one-stop-shop corporate services to startup companies. Ms. Fattal is a certified CPA (Isr.), and holds a BA in Accounting and
      Economics, and an MBA, both from Tel Aviv University.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Composition of the Board of Directors</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The members of our board of directors are appointed to three staggered director classes, which are as follows:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Class I consists of Stephen Squinto, Nissim Darvish and Joel Maryles, each with a term expiring at the 2022 annual meeting of shareholders.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Class II consists of Neil Cohen and Claude Nicaise, each with a term expiring at the 2023 annual meeting of shareholders.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Class III consists of Adi Mor and Alan Moses, each with a term expiring at the 2024 annual meeting of shareholders.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of management or a change of control of our company. Simultaneous with and
      contingent upon the approval of Dr. Pfost&#8217;s service as the Company&#8217;s Chief Executive Officer, he will commence his term as a Class III Director.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Director Independence</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Based upon information requested from and provided by each director concerning their background, employment and affiliations, including family relationships, our board of directors has determined that
      each of the directors is independent as defined under Nasdaq listing standards, with the exception of Dr. Mor. Our board of directors also determined that Nissim Darvish and Neil Cohen, who comprise the compensation committee and Neil Cohen and Joel
      Maryles, who comprise the corporate governance and nominating committee, all satisfy the independence standards for such committees established by the SEC and Nasdaq listing standards, as applicable. With respect to the Audit Committee, our board of
      directors has determined that Joel Maryles, Alan Moses and Claude Nicaise satisfy the independence standards for such committee established by Rule 10A-3 under the Exchange Act, the SEC and Nasdaq listing standards, as applicable, and that Joel
      Maryles is a financial expert under the rules of the SEC. The board of directors considered the relationships between such directors and certain of the investors of the Registrant and determined that such relationships did not affect such directors&#8217;
      independence under the standards of Nasdaq, or, where applicable, under SEC rules.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Board Committees</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Our board of directors has established three standing committees to assist it in fulfilling its responsibilities to the Registrant and its shareholders: the audit committee, the compensation committee
      and the corporate governance and nominating committee. Each committee acts pursuant to a written charter, each of which has been posted in the &#8220;Investor Relations&#8221; section of Chemomab&#8217;s website accessible at www.chemomab.com. Each committee reviews
      its charter on an annual basis. In addition to the three standing committees, our board of directors may approve from time to time the creation of other committees to assist the board in carrying out its duties.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Audit Committee</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The functions of the audit committee under Companies Law include identifying and addressing flaws in the business management of the Company, reviewing and approving related party transactions,
      establishing whistleblower procedures, overseeing our internal audit system and the performance of its internal auditor, and assessing the scope of the work and recommending the fees of our independent accounting firm. In addition, the audit
      committee is required to determine whether certain related party actions and transactions are &#8220;material&#8221; or &#8220;extraordinary&#8221; for the purpose of the requisite approval procedures under the Companies Law and to establish procedures for considering
      proposed transactions with a controlling shareholder.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">11</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In accordance with U.S. federal securities laws and Nasdaq requirements, our audit committee is also responsible for the appointment, compensation and oversight of the work of its independent auditors
      and for assisting the board of directors in monitoring financial statements, the effectiveness of internal controls and compliance with legal and regulatory requirements.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The members of the audit committee are Joel Maryles, Alan Moses and Claude Nicaise. Joel Maryles is the chairperson of the audit committee and is a financial expert under the rules of the SEC. Our
      board of directors has concluded that the composition of the audit committee meets the requirements for independence under the rules and regulations of Nasdaq and the SEC.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Compensation Committee</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The functions of the compensation committee under the Companies Law include recommending to the board of directors, for ultimate shareholder approval by a special majority, a policy governing the
      compensation of directors and officers based on specified criteria, reviewing modifications to and implementing such compensation policy from time to time, and approving the actual compensation terms of directors and officers prior to approval by the
      board of directors.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The members of the compensation committee are Nissim Darvish and Neil Cohen. Nissim Darvish is the chairperson of the compensation committee. Our board of directors has determined that each member of
      the compensation committee is independent within the meaning of the independent director guidelines of Nasdaq and under Rule 10C-1 under the Exchange Act.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Corporate Governance and Nominating Committee</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The corporate governance and nominating committee evaluates and recommends to the board of directors nominees for each election of directors and helps oversee our regulatory and compliance matters.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The members of the corporate governance and nominating committee are Neil Cohen and Joel Maryles. Neil Cohen is the chairperson of the corporate governance and nominating committee. Our board of
      directors has determined that each member of the corporate governance and nominating committee is independent within the meaning of the independent director guidelines of Nasdaq.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">12</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXECUTIVE COMPENSATION</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Director Compensation</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Chemomab currently pays its independent, non-employee Chairman of the Board annual director fees of $65,000 and grants to him options from time to time.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Chemomab Executive Compensation</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The aggregate amounts of salaries, consulting and director fees, pension, retirement and other similar benefits, and share-based compensation, that were payable to Chemomab Ltd.&#8217;s executive officers
      and directors and/or to their respective affiliates in respect of employment, consulting and directorship agreements and arrangements (which includes other amounts described in the &#8220;<font style="font-style: italic;">Director and Officer Compensation</font>&#8221;
      section of Amendment No. 1 to the Registration Statement on Form S-4, filed with the SEC on February 10, 2021 and which is incorporated by reference herein) during the year ended December 31, 2020 is set forth in the below table. The table does not
      include any amounts that Chemomab paid to reimburse any of such persons for costs incurred in providing it with services during that period.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z9a38bf3e6ccc42fcb6925698d94ee029">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">(in thousands)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Salary, Fees<br>
              and Related<br>
              Benefits</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pension,<br>
              Retirement<br>
              and<br>
              Other Similar<br>
              Benefits</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Share Based<br>
              Compensation</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 64%;">
            <div style="text-indent: -8.65pt; margin-left: 8.65pt; line-height: 1.25;">All directors and senior management as a group, consisting of 6 persons</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">671</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">78</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">91</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Chemomab compensates its directors and senior management team in accordance with the recommendation of its compensation committee and, generally, subject to the approval of our board of directors and
      shareholders. That compensation will generally need to be consistent with the terms of our compensation policy, which will require periodic approval, in accordance with the requirements of the Companies Law.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">On March 15, 2021, our shareholders approved an amendment to the compensation terms of our current and future directors, and related amendments to our compensation policy, which went effective on March
      16, 2021. Additionally, at our annual general meeting that took place on July 19, 2021, our shareholders approved an updated compensation policy for executive officers and directors, in accordance with the terms set forth below.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic;">Cash Compensation</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Our directors are entitled to certain cash fee amounts annually in respect of each of board service and board committee service. The amendment sets maximum director cash fee levels higher under the
      compensation policy than what we will pay to the board members in practice, in order to maintain flexibility under the compensation policy in the event that we desire to increase the fees at a later time. Any such increase in cash fees for the
      directors will require shareholder approval pursuant to the requirements of the Companies Law.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="zeba1f5e498744d5baf771501513e1411">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Actual Cash Fees Paid</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Cash Fee Upper Limit<br>
              Under the Proposed<br>
              Compensation Policy</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
            <div style="line-height: 1.25;"><font style="font-style: italic;">Annual Cash Fees</font>:</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Each board member, other than the Chairman of the Board</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">35,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">50,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
            <div style="line-height: 1.25;">Chairman of the Board</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">65,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">100,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">
            <div style="text-align: center; line-height: 1.25;">(in addition to this amount,<br>
              the Chairman may receive<br>
              annual fees for board<br>
              committee service)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">
            <div style="text-align: center; line-height: 1.25;">(this maximum cannot be<br>
              exceeded even after including<br>
              any additional fees payable for board<br>
              committee service)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;"><font style="font-style: italic;">Annual Fees for Board Committee Service</font>:</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-style: italic;">Committee Chairpersons:</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Audit Committee</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">15,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">15,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Compensation Committee</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">10,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">15,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Nominating / Governance Committee</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">8,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">15,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;"><font style="font-style: italic;">Other Committee Members</font>:</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Audit Committee</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">7,500</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">7,500</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25;">Compensation Committee</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">5,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
            <div style="line-height: 1.25;">7,500</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Nominating / Governance Committee</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">4,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">7,500</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
        </tr>

    </table>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">13</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic;">Equity Compensation</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The amendment to the compensation policy implements terms for actual equity compensation that will be granted to directors on a regular basis. We believe this will better ensure the tying of the
      performance of the Company to the compensation of its directors. As with the cash fee program for directors, the maximum director equity grant levels are anticipated to be higher under the compensation policy than what we will grant to the board
      members in practice, in order to maintain flexibility under the policy in the event that we desire to increase the amount of the equity grant at a later time. Any such increase in equity grant amounts for the directors will anyway be subject to the
      shareholder approval requirements under the Companies Law. The following is the equity grant levels for directors:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z2088e5f392954f97865b681f701d738b">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Actual<br>
              Equity<br>
              Grant Level<br>
              for<br>
              Directors</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Equity<br>
              Grant Upper<br>
              Limit Under<br>
              the Proposed<br>
              Compensation Policy</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-indent: -9pt; margin-left: 9pt; line-height: 1.25; font-style: italic;">Initial Option Grant (upon initial election to the board of directors):</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -9pt; margin-left: 9pt; line-height: 1.25;">Each board member, other than the Chairman of the Board:</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">0.1</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">0.4</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="text-indent: -9pt; margin-left: 9pt; line-height: 1.25;">Chairman of the Board&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">0.2</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">1.0</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -9pt; margin-left: 9pt; line-height: 1.25; font-style: italic;">Annual Option Grant (first annual grant to be allocated one year following the initial grant):</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="text-indent: -9pt; margin-left: 9pt; line-height: 1.25;">Each board member, other than the Chairman of the Board:</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">0.05</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">0.4</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -9pt; margin-left: 9pt; line-height: 1.25;">Chairman of the Board&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">0.1</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="line-height: 1.25;">1.0</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Employment Agreements</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic;">Employment Agreement with our Outgoing Chief Executive Officer, Chief Scientific Officer</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Under the employment agreement, dated April 25, 2013, as amended (most recently as of July 2021) that Chemomab Ltd. entered into with its then-Chief Executive Officer (currently Chief Scientific
      Officer), Dr. Adi Mor (which contract was assumed by our company as a result of the consummation of the Merger), Dr. Mor is entitled to a gross monthly salary of NIS 52,500 (approximately $16,150). Dr. Mor is also entitled to an annual performance
      bonus in the aggregate amount of $75,000, subject to her meeting certain performance milestones, as to be determined by our board of directors on an annual basis. Besides base salary and bonus, Dr. Mor receives under the agreement other benefits that
      are provided for by Israeli law or that are customary for senior executives in Israel, including reimbursement for reasonable expenses incurred in connection with her services, and the right to use (including certain related fixed and variable costs
      in respect of) a leased car and a cellular phone. In lieu of a leased car, Dr. Mor may elect to receive a monthly car allowance payment. Dr. Mor is furthermore entitled to company contributions equivalent to 8.33%, 2.5%, and 5% of her gross monthly
      salary towards certain severance, disability and tax-advantaged savings funds (known as a manager&#8217;s insurance policy), respectively. Dr. Mor also contributes 5.5% of her gross monthly salary towards the manager&#8217;s insurance policy. The employment
      engagement is terminable by either party upon 60 days prior written notice, and contains customary provisions regarding noncompetition, confidentiality of information and assignment of inventions. As required under Israeli law, the terms of Dr. Mor&#8217;s
      engagement with Chemomab Ltd. were approved by Chemomab Ltd.&#8217;s board of directors and shareholders.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">14</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Dr. Mor has been granted, pursuant to her employment agreement, an aggregate of 10,239 options to purchase Chemomab Ltd. shares, of which 8,959 have vested or will vest within 60 days of September 1,
      2021, under Chemomab Ltd.&#8217;s share option and incentive plan (which was assumed by our company in the Merger). The options were converted to Chemomab options based on the exchange ratio in the merger agreement for the Merger (the &#8220;Merger Agreement&#8221;),
      with a reciprocal adjustment to exercise price.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">At the annual meeting of our shareholders that took place on July 19, 2021, our shareholders approved an amendment to Dr. Mor&#8217;s compensation, pursuant to which Dr. Mor will receive: (a) an annual base
      salary of $249,000; (b) certain social benefits, including <font style="font-style: italic;">keren hishtalmut</font> (advanced study fund); (c) car and car related expenses; (d) a target annual gross cash bonus of $100,000 that can be achieved
      pursuant to certain pre-determined objectives according to the discretion of the board of directors; and (e) a one-time cash bonus in the aggregate gross amount of $90,000 in connection with Dr. Mor&#8217;s contribution to the consummation of the Merger
      and recent financing transaction.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic;">Employment Agreement with Chemomab Chief Medical Officer</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Under the employment agreement, dated March 1, 2019, that Chemomab Ltd. entered into with its Chief Medical Officer, Dr. Arnon Aharon (which contract was assumed by our company as a result of the
      consummation of the Merger), Dr. Aharon is entitled to a gross monthly salary of NIS 55,000 (approximately $17,000). Dr. Aharon is also entitled to an annual performance bonus of up to 20% of his annual salary, subject to his meeting certain
      performance criteria, as to be set forth in a personal bonus policy. Besides base salary and bonus, Dr. Aharon receives under the agreement other benefits that are provided for by Israeli law or that are customary for senior executives in Israel,
      including reimbursement for reasonable expenses incurred in connection with his services, and the right to a monthly travel allowance of NS 3,000 (approximately $938). Dr. Aharon is furthermore entitled to company contributions equivalent to 8.33%,
      2.5%, 7.5% and at least 5% of his gross monthly salary towards certain severance, disability, study fund and tax-advantaged savings funds (known as a manager&#8217;s insurance policy or pension), respectively. Dr. Aharon also contributes 6% and 2.5% of his
      gross monthly salary towards the manager&#8217;s insurance policy/pension and study fund, respectively. The employment engagement is terminable immediately by either party upon two months&#8217; prior written notice, and contains customary provisions regarding
      noncompetition, confidentiality of information and assignment of inventions. As required under Israeli law, the terms of Dr. Aharon&#8217;s engagement with Chemomab Ltd. were approved by Chemomab Ltd.&#8217;s board of directors.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Dr. Aharon has been granted, pursuant to his employment agreement, an aggregate of 5,849 options to purchase our shares, of which 4,279 have vested or will vest within 60 days of September 1, 2021),
      under Chemomab Ltd.&#8217;s share option and incentive plan (which was assumed by our company in the Merger). The options were converted to the Company's options based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise
      price.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Share Incentive Plans</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We maintain (i) the 2011 Share Option Plan (the &#8220;2011 Plan&#8221;), (ii) the 2017 Equity-Based Incentive Plan (the &#8220;2017 Plan&#8221;) and (iii) the Chemomab Ltd. 2015 Share Incentive Plan (the &#8220;2015 Plan&#8221;), &#8201;which
      was assumed by our company from Chemomab Ltd. upon the effectiveness of the Merger. At that time, outstanding options under the 2015 Plan became exercisable for such number of ADSs of our company (formerly known as Anchiano Therapeutics Ltd.) as was
      determined based on the exchange ratio in the Merger Agreement, with a reciprocal adjustment to exercise price. As of September 1, 2021, a total of 1,422,153 of our ADSs were reserved for issuance under the 2015 Plan, of which 67,064 ADSs had been
      issued pursuant to previous exercises options, and 645,183 ADSs&#160; were issuable under outstanding options. Of such outstanding options, options to purchase 377,908 ADSs had vested and were exercisable as of that date, with a weighted average exercise
      price of $2.17 per ADS.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">15</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">2011 Plan</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">On December 19, 2011, our board of directors adopted 2011 Plan to allocate options to purchase our ordinary shares to our directors, officers, employees and consultants, and those of our affiliated
      companies (as such term is defined under the 2011 Plan), or the Grantees. The 2011 Plan is administered by our board of directors or a committee that was designated by our board of directors for such purpose (the &#8220;Administrator&#8221;).</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Under the 2011 Plan, we may grant options to purchase ordinary shares (&#8220;Options&#8221;), under four tracks: (i) Approved 102 capital gains Options through a trustee, which was approved by the Israeli Tax
      Authority in accordance with Section 102(a) of the Israeli Income Tax Ordinance (&#8220;ITO&#8221;), and granted under the tax track set forth in Section 102(b)(2) of the ITO, or the Approved 102 Capital Gains Options. The holding period under this tax track is
      24 months from the date of allocation of Options to the trustee or such period as may be determined in any amendment of Section 102 of the ITO, or any applicable tax ruling or guidelines; (ii) Approved 102 Earned Income Options through a trustee,
      granted under the tax track set forth is Section 102(b)(1) of the ITO, or the Approved 102 Earned Income Options. The holding period under this tax track is 12 months from the date of allocation of Options to the trustee or such period as may be
      determined in any amendment of Section 102 of the ITO; (iii) Unapproved 102 Options (the Options will not be allocated through a trustee and will not be subject to a holding period), or the Unapproved 102 Options; and (iv) 3(i) Options (the Options
      will not be subject to a holding period). These Options shall be subject to taxation pursuant to Section 3(i) of the ITO, or Section 3(i).</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Options pursuant to the first three tax tracks (under Section 102 of the ITO) can be granted to our employees and directors and the grant of Options under Section 3(i) can be granted to our consultants
      and controlling shareholders (a controlling shareholder is defined under the Section 102 of the ITO is a person who holds, directly or indirectly, alone or together with a &#8220;relative,&#8221; (i) the right to at least 10% of the company&#8217;s issued capital or
      10% of the voting power; (ii) the right to hold at least 10% of the company&#8217;s issued capital or 10% of the voting power, or the right to purchase such rights; (iii) the right to receive at least 10% of the company&#8217;s profits; or (iv) the right to
      appoint a company&#8217;s director). Grantees who are not Israeli residents may be granted options that are subject to the applicable tax laws in their respective jurisdictions.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We determine, in our sole discretion, under which of the first three tax tracks above the Options are granted and we notify the Grantee in a grant letter, as to the elected tax track. As mentioned
      above, consultants and controlling shareholders can only be granted Section 3(i) Options.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The number of ordinary shares authorized to be issued under the 2011 Plan will be proportionately adjusted for any increase or decrease in the number of ordinary shares issued as a result of a
      distribution of bonus shares, change in our capitalization (split, combination, reclassification of the shares or other capital change), or issuance of rights to purchase ordinary shares or payment of a dividend. We will not allocate fractions of
      ordinary shares and the number of ordinary shares shall be rounded up to the closest number of ordinary shares.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Unless otherwise determined by the Administrator, the exercise price of an Option granted under the 2011 Plan will be the average of the market price of the Company&#8217;s ordinary shares during the 22
      business days prior to the date on which our board of directors authorized the grant of Options; provided, however, that such exercise price cannot be lower than the market price at the close of the trading day at which it was granted by our board of
      directors. The exercise price will be specified in the grant letter every Grantee received from us in which the Grantee notifies of the decision to grant him/her Options under the 2011 Plan.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Unless otherwise determined by the Administrator, the Options granted under the Plan will become vested and may be exercised in 16 equal portions of 6.25% of the total number of Options, at the end of
      each quarter following the day the Options were granted. Unless otherwise determined by our board of directors, the Options may be exercised for ten years following the date of grant, unless terminated earlier, and as long as the Grantee is employed
      by the Company (or by an affiliated company), or provides service to the Company (or an affiliated company).</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The Administrator may, in its absolute discretion, accelerate the time at which Options granted under the 2011 Plan or any portion of which will vest.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Unless otherwise determined by the Administrator, in the event that the Grantee&#8217;s employment was terminated, not for Cause (as defined in the 2011 Plan), the Grantee may exercise that portion of the
      Options that had vested as of the date of such termination until the end of the specified term in the grant letter or the 2011 Plan. The portion of the Options that had not vested at such date, will be forfeited and can be re-granted according to the
      terms of the 2011 Plan.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">16</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">2017 Plan</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">On February 22, 2017, our board of directors adopted the 2017 Plan to allocate a variety of share-based awards to our directors, officers, employees, consultants, advisors and service providers, and
      those of our affiliates (companies that control us, are controlled by us or are under common control with us) (the &#8220;Participants&#8221;). The 2017 Plan is currently administered by our board of directors, and may be administered by a committee designated
      by our board of directors for such purpose.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Under the 2017 Plan, we may grant options to purchase ordinary shares or ADSs, restricted shares or ADSs, restricted share units and other awards based on our ordinary shares, all of which are referred
      to as Awards. We may grant Awards under the same four tracks as described above with respect to the 2011 Plan, subject to the same conditions as apply for the 2011 Plan. In addition, we may grant incentive stock options and nonqualified stock options
      to Participants who are residents of the United States, and we may grant awards to Participants who are residents of other countries that comply with the laws of those jurisdictions.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The number of ordinary shares authorized to be issued under the 2017 Plan will be proportionately adjusted for any increase or decrease in the number of ordinary shares issued as a result of a
      distribution of bonus shares, change in our capitalization (split, combination, reclassification of the shares or other capital change), issuance of rights to purchase ordinary shares or payment of a dividend. We will not allocate fractions of
      ordinary shares and the number of ordinary shares shall be rounded down to the closest number of ordinary shares.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In the event of a (i) merger, consolidation, amalgamation or the like with or into another corporation, (ii) an acquisition (including an exchange) of all or substantially all of our ordinary shares,
      (iii) the sale of all or substantially all of our assets, or (iv) any other event determined by the Administrator to have a similar impact, then &#8211; unless otherwise determined by our board of directors in its sole and absolute discretion &#8211; any Award
      then outstanding will be assumed or an equivalent Award shall be substituted by the successor corporation, under substantially the same terms as the Award.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The exercise price of an option granted under the 2017 Plan will, in general, be no less than the fair market value of the Company&#8217;s ordinary shares on the date of grant, subject to any minimum
      exercise price prescribed by law. The Administrator determines the vesting provisions for each Award and may, in its sole discretion, accelerate the time at which options granted under the 2017 Plan will vest. Unless otherwise determined by the
      Administrator, options may be exercised for ten years (five years in the case of an incentive stock option granted to a 10% shareholder), and as long as the Participant is employed by the Company (or by an affiliated company) or provides services to
      the Company (or an affiliated company). If a Participant&#8217;s employment is terminated, other than for cause, the Participant may generally exercise vested options for a limited period following termination<font style="font-style: italic;">.</font></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In accordance with the terms of the 2017 Plan, on January 1 of each calendar year during the term of the 2017 Plan, the number of shares available for issuance under the 2017 Plan shall be increased by
      4% of the total number of company shares outstanding on December 31 of the immediately preceding calendar year, or such lesser number as shall be determined by the administrator of the plan, subject to adjustments required for recapitalization
      events.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">2015 Plan</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In November 2015, Chemomab Ltd.&#8217;s board of directors adopted, and its shareholders subsequently approved, the 2015 Plan. The 2015 Plan provides for the grant of options, restricted shares, restricted
      share units and other share-based awards to Chemomab Ltd.&#8217;s (following the Merger, the Company&#8217;s or Chemomab&#8217;s) and its subsidiaries&#8217; and affiliates&#8217; directors, employees, officers, consultants, advisors, and any other person whose services are
      considered valuable to Chemomab or its affiliates. Any such grants are intended to incentivize the foregoing persons to continue as service providers, to increase their efforts on Chemomab&#8217;s behalf or on behalf of its subsidiaries or affiliates, and
      to promote the success of its business.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">17</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The 2015 Plan is administered by Chemomab&#8217;s board of directors or by a committee designated by the board of directors, which determines, subject to Israeli law, the grantees of awards and the terms of
      the grant, including, exercise prices, vesting schedules, acceleration of vesting and the other matters necessary in the administration of the 2015 Plan. The 2015 Plan enables Chemomab to issue awards under various tax regimes, including, without
      limitation, pursuant to Section 102 of the Israeli Income Tax Ordinance, or the Ordinance, and under Section 3(i) of the Ordinance and Section 422 of the United States Internal Revenue Code of 1986, as amended, or the Code.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The 2015 Plan provides that options granted to Chemomab&#8217;s employees, directors and officers who are not controlling shareholders and who are considered Israeli residents are intended to qualify for
      special tax treatment under the &#8220;capital gain track&#8221; provisions of Section 102(b) of the Ordinance. Chemomab&#8217;s Israeli non-employee service providers and controlling shareholders may only be granted options under Section 3(i) of the Ordinance, which
      does not provide for similar tax benefits.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Options granted under the 2015 Plan to U.S. residents may qualify as &#8220;incentive stock options&#8221; within the meaning of Section 422 of the Code, or may be non-qualified. The exercise price for &#8220;incentive
      stock options&#8221; must not be less than the fair market value on the date on which an option is granted, or 110% of the fair market value if the option holder holds more than 10% of Chemomab&#8217;s share capital.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Options and other awards granted under the 2015 Plan generally vest over four years commencing on the date of grant, such that 25% vests on the first anniversary of the date of grant and an additional
      6.25% vests at the end of each subsequent calendar quarter over the course of the next three years, provided that the participant remains continuously employed or engaged by Chemomab.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Options, other than certain incentive share options, that are not exercised within ten years from the grant date expire, unless otherwise determined by Chemomab&#8217;s board of directors or its designated
      committee, as applicable. Share options that qualify as &#8220;incentive stock options&#8221; and are granted to a person holding more than 10% of Chemomab&#8217;s voting power will expire within five years from the date of the grant. In the event of the death of a
      grantee while employed by or performing service for Chemomab or its subsidiary or within three months after the date of the employee&#8217;s termination, or the termination of a grantee&#8217;s employment or services for reasons of disability, the grantee, or in
      the case of death, his or her legal successor, may exercise options or other awards that have vested prior to termination within a period of one year from the date of disability or death. If Chemomab terminates a grantee&#8217;s employment or service for
      cause, all of the grantee&#8217;s vested and unvested options or other awards will expire on the date of termination. If a grantee&#8217;s employment or service is terminated for any other reason, the grantee may generally exercise his or her vested options or
      other award within three months of the date of termination. Any expired or unvested options return to the pool and become available for reissuance. From time to time, Chemomab may consider issuing options with slightly different terms or
      accelerating, extending or otherwise modifying options in accordance with applicable law and regulation and the terms of the 2015 Plan.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">In the event of a merger or consolidation of Chemomab, or a sale of all, or substantially all, of Chemomab&#8217;s shares or assets or other transaction having a similar effect on Chemomab, then without the
      consent of the option holder, Chemomab&#8217;s board of directors or its designated committee, as applicable, may, but is not required, to (i) cause any outstanding award to be assumed or an equivalent award to be substituted by such successor corporation,
      or (ii) in case the successor corporation does not assume or substitute the award (a) provide the grantee with the option to exercise the award as to all or part of the shares or (b) cancel the options and pay in cash an amount determined by the
      board of directors or the committee as fair in the circumstances. Notwithstanding the foregoing, Chemomab&#8217;s board of directors or its designated committee may upon such event amend, modify or terminate the terms of any award, including conferring the
      right to purchase any other security or asset that the board of directors or the committee shall deem, in good faith, appropriate.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The 2015 plan was assumed by our company from Chemomab Ltd. upon the effectiveness of the Merger.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Compensation Committee Interlocks and Insider Participation</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Each member of the compensation committee of the Company is an &#8220;outside&#8221; director as that term is defined in Section 162 (m) of the Internal Revenue Code of 1986, as amended, a &#8220;non-employee&#8221; director
      within the meaning of Rule 16b-3 of the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of the Nasdaq. None of our executive officers serves as a member of the board of directors or
      compensation committee of any entity that has one or more executive officers on our board of directors or compensation committee.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">18</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL:</div>
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">APPROVAL OF THE EMPLOYMENT TERMS OF</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">DR. DALE PFOST, THE CHIEF EXECUTIVE OFFICER OF THE COMPANY</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 28.35pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">On September 1,&#160; 2021, the Company&#8217;s board of directors approved the appointment of Dr. Dale Pfost as Chief Executive Officer of the Company.&#160; Upon the commencement of his service, Dr. Adi Mor,
          will cease her service as the Company&#8217;s Chief Executive Officer, but will continue in her role as Chief Scientific Officer and a member of the board of directors.</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 28.35pt; line-height: 1.25;">Simultaneous with and contingent upon the approval of Dr. Pfost&#8217;s service as the Company&#8217;s Chief Executive Officer, he will commence his term as a Class III Director. Dr. Pfost will not be
        compensated for his service as a Class III director of the Company. In addition, and subject to the approval of Dr. Pfost&#8217;s service as the Company&#8217;s Chief Executive Officer and the commencement of his term as a Class III director, and after the
        current chairman of the board of directors, Mr. Stephen Squinto, steps down from such position (no later than June 30, 2022), Dr. Pfost will be elected to chairman of the board of directors, or, alternatively, he will have the right to identify a
        candidate to be elected&#160; as the chairman of the board of directors. In accordance with the Companies Law, the appointment of a chief executive officer to the position of chairman of the board of directors requires the approval of the company&#8217;s
        nominating committee, board of directors and shareholders (pursuant to a special majority), in that order.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 28.35pt; line-height: 1.25;">As required under the Companies Law, the employment terms of a chief executive officer require the approval of a company&#8217;s shareholders pursuant to a special majority. Accordingly, at the Special
        Meeting, our shareholders will be asked to approve the following proposed employment terms of Dr. Pfost, the Company&#8217;s incoming Chief Executive Officer:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="zfe2f792caa1446e4925148e4670654bb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 28.35pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
            <td style="width: auto; vertical-align: top;">
              <div>an annual base salary of $600,000 (the &#8220;Base Salary&#8221;);</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="zda1aaaa7bfd7448b847c6b47f01bfda4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 28.35pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(ii)</td>
            <td style="width: auto; vertical-align: top;">
              <div>an initial target annual cash incentive bonus of 50% of the Base Salary and an additional potential bonus of 10% of the Base Salary based on Dr. Pfost&#8217;s achievement of certain predetermined goals, which shall be determined at the
                discretion of the Company&#8217;s board of directors;</div>
            </td>
          </tr>

      </table>
    </div>
    <br>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 28.35pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(iii)</td>
            <td style="width: auto; vertical-align: top;">
              <div>
                <div style="line-height: 1.25;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">options to purchase&#160; 459,353 ADSs of the Company (the &#8216;Options&#8221;), constituting 3.5% of the outstanding and issued ADSs of the Company (on a fully diluted basis)
                    which will vest over a period of four (4) years with one quarter (1/4) of the Options vesting on the first anniversary of the grant date and the remainder in equal amounts over the ensuing 36 monthly periods, unless such options have
                    been cancelled in accordance with the terms and conditions of the 2015 Plan;</div>
                </div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 28.35pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right;">(iv)</td>
              <td style="width: auto; vertical-align: top;">
                <div>
                  <div style="line-height: 1.25;">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">In the event of termination of Dr. Pfost&#8217;s employment without Cause as the result of a merger or sale of all or substantially all of the Company&#8217;s capital stock
                      or assets, (i.e. a change in control of the Company), vesting of all unvested Options will accelerate and all unvested Options will immediately vest and become exercisable;</div>
                  </div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br>
        <div style="line-height: 1.25;">
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 28.35pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(v)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>
                    <div style="line-height: 1.25;">
                      <div style="font-family: 'Times New Roman',Times,serif;">In the event of termination of Dr. Pfost&#8217;s employment without Cause, other than as a result of a merger or sale of all or substantially all of the Company&#8217;s capital stock or
                        assets (i.e. a change in control of the Company) or if Dr. Pfost terminates his employment for Good Reason:</div>
                    </div>
                  </div>
                </td>
              </tr>

          </table>
        </div>
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.05pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 101.7pt; vertical-align: top; align: right;">
                    <div style="margin-left: 76.15pt; line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">any time-based Options then outstanding and due to vest on the twelve (12) month anniversary of Dr. Pfost&#8217;s employment commencement date will accelerate and
                        become exercisable if Dr. Pfost has been employed by the Company at such time for six (6) months or more but less than twelve (12) months; and</div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.05pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 101.7pt; vertical-align: top; align: right;">
                    <div style="margin-left: 76.15pt; line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">all time-based Options then outstanding will accelerate and become exercisable if Dr. Pfost has been employed by the Company at such time for twelve (12) months
                      or longer.</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 28.35pt;"><br>
                  </td>
                  <td style="width: 36pt; vertical-align: top; align: right;">(vi)</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>
                      <div style="line-height: 1.25;">a one-time signing bonus in an amount of $80,000;</div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;"><br>
              <div style="line-height: 1.25;">
                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                    <tr>
                      <td style="width: 28.35pt;"><br>
                      </td>
                      <td style="width: 36pt; vertical-align: top; align: right;">(vii)</td>
                      <td style="width: auto; vertical-align: top;">
                        <div>
                          <div style="line-height: 1.25;">
                            <div style="line-height: 1.25;">a one-time bonus in an amount of $80,000 upon the establishment of a new office in the United State and Dr. Pfost&#8217;s domiciling in the location of the new office, which will be payable within 15
                              days of such domiciling;</div>
                          </div>
                        </div>
                      </td>
                    </tr>

                </table>
              </div>
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;">
                  <div style="line-height: 1.25;">
                    <div><br>
                    </div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ce04c41340e04a64949c915a5a6198b4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                        <tr>
                          <td style="width: 28.35pt;"></td>
                          <td style="width: 36pt; vertical-align: top; align: right;">(viii)</td>
                          <td style="width: auto; vertical-align: top;">
                            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">25 days of Paid Time Off per year, capped at 50 days of accrued PTO; and</div>
                          </td>
                        </tr>

                    </table>
                    <div><br>
                    </div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="5f4fd4ea407b4a2c9710be30b760d0b5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                        <tr>
                          <td style="width: 28.35pt;"></td>
                          <td style="width: 36pt; vertical-align: top; align: right;">
                            <div style="text-align: justify; line-height: 1.25;">(ix)</div>
                          </td>
                          <td style="width: auto; vertical-align: top;">
                            <div style="text-align: justify; line-height: 1.25;">.certain severance benefits payable in the event that the Company terminates Dr. Pfost&#8217;s employment without Cause, provided that the total amount of the cash portion of
                              severance benefits will not exceed two hundred percent (200%) of Dr. Pfost&#8217;s annual base salary at the rate in effect on the date of termination.</div>
                          </td>
                        </tr>

                    </table>
                    <div style="line-height: 1.25;"> </div>
                    <br>
                    <div style="text-indent: 20.15pt; margin-left: 5.3pt; line-height: 1.25;">If approved, following the grants made under this proposal, the Company will have outstanding, under its incentive plans, options to purchase approximately
                      1,106,141 of its ADSs, representing, approximately 8.4% of our total issued and outstanding share capital on a fully diluted basis.</div>
                    <div style="text-indent: 20.15pt; margin-left: 5.3pt; line-height: 1.25;"> <br>
                    </div>
                    <div style="text-indent: 28.35pt; line-height: 1.25;">
                      <div style="text-indent: 20.15pt; margin-right: 10.85pt; margin-left: 5.3pt; line-height: 1.25;">The Company&#8217;s compensation committee and board of directors approved the terms described above as they believe that it would serve as an
                        appropriate long-term retention and performance incentive and advance the objectives of the Company, its work plan and long-term strategy. The Company&#8217;s compensation committee and board of directors reviewed and considered a
                        comprehensive benchmark analysis prepared by an independent compensation advisor, Deloitte Israel &amp; Co. (&#8220;Deloitte&#8221;) in connection with the terms of compensation of chief executive officers of 19 peer companies. The foregoing
                        peer group was constructed with careful consideration and represents an appropriate comparison pool based on such peer companies&#8217; industry, size, revenues and maturity stage. According to Deloitte&#8217;s recent survey, Dr. Pfost&#8217;s total
                        compensation falls at the high end in comparison to the chief executive officers of the above mentioned group of 19 peer companies.</div>
                    </div>
                    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">19</font></div>
                      <div style="page-break-after: always;" id="DSPFPageBreak">
                        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                    </div>
                    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                    </div>
                    <div style="text-indent: 28.35pt; line-height: 1.25;">The Company&#8217;s compensation committee and board of directors reviewed compensation of additional peer companies and further concluded that the proposed compensation is reasonable and
                      fair given the proven track record of Dr. Pfost, the responsibilities assigned to him&#160; and the expectations with respect to his performance.</div>
                    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                    </div>
                    <div style="text-indent: 28.35pt; line-height: 1.25;">The biographical information for Dr. Dale Pfost appears below:</div>
                    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                    </div>
                    <div style="text-indent: 28.35pt; line-height: 1.25;"><font style="font-style: italic;">Dr. Dale Pfost</font> has 35 years of experience as an entrepreneur, investor and business executive. Since 2019, Dr. Pfost has served as Chief
                      Executive Officer and Chairman of the Board of Lodo Therapeutics Corporation. From 2009 until 2019, Dr. Pfost served in a variety of roles at Microbiome Therapeutics, LLC, a company which he co-founded, including as a board member and
                      Chief Executive Officer from 2009 until 2010 and again from 2016 until 2019. From 2010 until 2019, he served as a General Partner at Advent Life Sciences. From 2013 until 2017, Dr. Pfost served in a variety of roles at Vestagen
                      Protective Technologies, including Chairman, Executive Chairman from 2013 until 2017, and Chief Executive Officer from 2015 until 2016. Prior to that, Dr. Pfost held various executive positions at the following companies: Chief
                      Executive Officer at Receptor Biologix Inc. (from 2008 until 2009), President, Chief Executive Officer and Chairman at Acuity Pharmaceuticals, Inc. (from 2003 until 2007), President, Chief Executive Officer and Chairman at Orchid
                      Biosciences, Inc. (from 1996 until 2002), President, Chief Executive Officer and Managing Director at Oxford Glycosciences Ltd. (from 1988 until 1996) and Director of Robotics and Automated Chemistry Systems at Smithkline Beckman from
                      1984 until 1988. In addition to the foregoing, Dr. Pfost has served on the board of directors of several companies, including Bioelectronica Corp., AxoSim, Inc., JMB Companies LLC, Aura Bioscience, Louisiana BIO and CN Creative. Dr.
                      Pfost earned his BS from the University of California, Santa Barbara, and a PhD in physics from Brown University.</div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Proposed Resolution</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">It is proposed that the following resolution be adopted at the Special Meeting:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;&#8220;<font style="font-weight: bold;">RESOLVED</font>, that the terms of employment of Dr. Dale Pfost, who was engaged as the Chief Executive Officer of the Company on [&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ], 2021, as
      detailed in the proxy statement dated [&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ], 2021, be, and hereby are, approved in all respects.&#8221;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Required Vote</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Please see &#8220;What are the Voting Requirements to Approve the Proposals?&#8221; above. As described therein, in addition to approval by an ordinary majority, the proposal requires approval by a special
      majority in order to be duly approved under the Companies Law.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Board Recommendation</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Our Board of Directors recommends a vote FOR the proposal included in the proposal.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">20</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">ANNUAL REPORT AND RELATED REPORTS TO SHAREHOLDERS</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Both our (i) Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on March 9, 2021 (the &#8220;Annual Report&#8221;) and (ii) Current Report on Form 8-K/A, filed with the SEC
      on April 14, 2021 (the &#8220;8-K&#8221;), which provides additional information about us, including substantive information related to Chemomab Ltd., the operating company acquired by us in connection with the Merger, will be distributed to all shareholders
      entitled to vote along with the proxy materials. Additional copies of our Annual Report and the 8-K are available on the Internet at http://www.sec.gov and http://www.chemomab.com and are also available in paper form without charge upon written
      request to Chemomab Therapeutics Ltd., Kiryat Atidim, Building 7, Tel-Aviv, Israel 6158002.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">HOUSEHOLDING OF PROXY MATERIALS</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more shareholders
      sharing the same address by delivering a single proxy statement addressed to those shareholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for shareholders and cost savings for companies.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">This year, a number of brokers with account holders who are shareholders of our Company will be &#8220;householding&#8221; our proxy materials. A single proxy statement may be delivered to multiple shareholders
      sharing an address unless contrary instructions have been received from the affected shareholder. Once a shareholder has received notice from its broker that it will be &#8220;householding&#8221; communications to such shareholder&#8217;s address, &#8220;householding&#8221; will
      continue until such shareholder is notified otherwise or until such shareholder notifies its broker or us that it no longer wishes to participate in &#8220;householding.&#8221; If, at any time, a shareholder no longer wishes to participate in &#8220;householding&#8221; and
      would prefer to receive a separate proxy statement and annual report (for annual meetings) in the future, such shareholders may (1) notify its broker or (2) direct its written request to: Chemomab Therapeutics Ltd., Kiryat Atidim, Building 7,
      Tel-Aviv, Israel 6158002. Shareholders who currently receive multiple copies of the proxy statement at their address and would like to request &#8220;householding&#8221; of their communications should contact their broker. In addition, we will promptly deliver,
      upon written or oral request to the address or telephone number above, a separate copy of the proxy statement to such shareholders at a sharedaddress to which a single copy of the documents was delivered.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">21</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">OTHER INFORMATION</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Section 16(a) Beneficial Ownership Reporting Compliance</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Section 16(a) of the Exchange Act requires our directors, executive officers and holders of more than 10% of our ordinary shares to file with the SEC reports regarding their ownership and changes in
      ownership of our equity securities. We believe that all Section 16 filings requirements were met by our officers and directors during the fiscal year ended December 31, 2020.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Other Matters</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">The board of directors currently knows of no other business to be transacted at the Special Meeting, other than as set forth in the Notice of Special General Meeting of Shareholders; but, if any other
      matter is properly presented at the Special Meeting, the persons named in the enclosed form of proxy will vote upon such matters in accordance with their best judgment.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Where to Find More Information</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Our reports on Forms 10-K, 8-K and formerly on Forms 20-F and 6-K and all amendments to those reports are available without charge through our website, <u>www.chemomab.com, </u>as soon as reasonably
      practicable after they are electronically filed with, or furnished to, the SEC. Our Code of Business Conduct and Code of Ethics, and our Committee Charters are also available at our website address mentioned&#160;&#160; above. The content of our website,
      however, is not part of this proxy statement. You may request a copy of our SEC filings, as well as the foregoing corporate documents, at no cost to you, by writing to the Company address appearing in this proxy statement or by calling us at +972-
      773310156.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Our SEC filings and submissions are also available to the public from commercial document retrieval services and at the Internet at http://www.sec.gov.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" id="DSPFPageNumber">22</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zafc45af58de64f9ca6791587eb565a2b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3%; vertical-align: top; background-color: #000000;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 39%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top; background-color: #000000;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 55%; vertical-align: top;" colspan="3">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45.1%; vertical-align: top;" colspan="4">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Special General Meeting of</div>
          </td>
          <td style="width: 9.94%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td style="width: 44.96%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;Special General Meeting of Chemomab Therapeutics Ltd.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45.1%; vertical-align: top;" colspan="4">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Chemomab Therapeutics Ltd.</div>
          </td>
          <td style="width: 9.94%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td style="width: 44.96%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;to be held on October 25, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45.1%; vertical-align: top;" colspan="4">
            <div style="line-height: 1.25; font-weight: bold;">Date:&#160;&#160;&#160;&#160;&#160;&#160; October 25, 2021</div>
          </td>
          <td style="width: 9.94%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td style="width: 44.96%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;For Holders as of October 1, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45.1%; vertical-align: top;" colspan="4">
            <div style="line-height: 1.25; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;See Voting Instruction On Reverse Side.</div>
          </td>
          <td style="width: 9.94%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td style="width: 44.96%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45.1%; vertical-align: top;" colspan="4">
            <div style="line-height: 1.25; font-weight: bold;">Please make your marks like this: <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;Use pen only</div>
          </td>
          <td style="width: 9.94%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td style="width: 44.96%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zc0ad5f6a4c7149fa906e65c34f14f209" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 2.11%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.93%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.37%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.48%; vertical-align: middle;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">For</div>
          </td>
          <td style="width: 7.27%; vertical-align: middle;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Against</div>
          </td>
          <td style="width: 7.39%; vertical-align: middle;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Abstain</div>
          </td>
          <td style="width: 4.97%; vertical-align: middle;" rowspan="16">
            <div style="text-align: center; line-height: 1.25;"><img src="sc.jpg">&#160;&#160; </div>
          </td>
          <td style="width: 48.48%; vertical-align: middle;" rowspan="16" colspan="7">
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="text-align: center; line-height: 1.25;"><img src="sc3.jpg">&#160; <br>
            </div>
            <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#9679;&#160;Mark, sign and date your Voting Instruction Form.</div>
            <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#9679;&#160;Detach your Voting Instruction Form.</div>
            <div style="line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#9679;&#160;Return your Voting Instruction Form in the postage-paid envelope provided.</div>
            <div style="line-height: 1.25;">&#160;</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">All votes must be received by 12:00 p.m. EST, on October [___], 2021.</div>
            <div style="text-align: center; line-height: 1.25;">&#160; <br>
            </div>
            <div style="line-height: 1.25; font-weight: bold;">PROXY TABULATOR FOR</div>
            <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
            <div style="line-height: 1.25; font-weight: bold;">P.O. BOX 8016</div>
            <div style="line-height: 1.25; font-weight: bold;">CARY, NC 27512-9903</div>
            <div style="line-height: 1.25;">&#160;</div>
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
            <div style="text-align: center; line-height: 1.25;">&#160;<br>
            </div>
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
            <div style="text-align: center; line-height: 1.25;"> <br>
            </div>
            <div style="text-align: center; line-height: 1.25;"> <br>
            </div>
            <div style="text-align: center; line-height: 1.25;"> <br>
            </div>
            <div style="text-align: center; line-height: 1.25;"> <br>
            </div>
            <div style="text-align: center; line-height: 1.25;"> <br>
            </div>
            <div style="text-align: center; line-height: 1.25;"> <br>
            </div>
            <div style="text-align: center; line-height: 1.25;"> <br>
            </div>
            <div style="text-align: center; line-height: 1.25;"> <br>
            </div>
            <div style="text-align: center; line-height: 1.25;"> <br>
            </div>
            <div style="text-align: center; line-height: 1.25;"> <br>
            </div>
            <div style="line-height: 1.25;"><img src="sc2.jpg"></div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: top;">
            <div style="line-height: 1.25;">1.</div>
          </td>
          <td style="width: 23.3%; vertical-align: top;" colspan="3">
            <div style="text-align: justify; line-height: 1.25;">To approve the employment terms of Dr. Dale Pfost, the Chief Executive Officer of the Company;</div>
          </td>
          <td style="width: 6.48%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
          </td>
          <td style="width: 7.27%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
          </td>
          <td style="width: 7.39%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.93%; vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.37%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.48%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Yes</div>
          </td>
          <td style="width: 7.27%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">No</div>
          </td>
          <td style="width: 7.39%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.93%; vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">a.</div>
          </td>
          <td style="width: 21.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">I hereby confirm that I am NOT a controlling shareholder and I do NOT have a conflict of interest (referred to as a &#8220;personal interest&#8221; under the Israeli Companies Law) in the approval of the
              proposal.</div>
          </td>
          <td style="width: 6.48%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
          </td>
          <td style="width: 7.27%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
          </td>
          <td style="width: 7.39%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.93%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.37%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.48%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.27%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.39%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.93%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.37%; vertical-align: middle;">
            <div style="text-align: justify; line-height: 1.25;">(Please note: Please check &#8220;Yes&#8221; to confirm that you are not a controlling and lack a conflict of interest in the approval of the proposal. If you do not mark either Yes or No, your shares
              will not be voted on the proposal).</div>
          </td>
          <td style="width: 6.48%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.27%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.39%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23.3%; vertical-align: middle;" colspan="3">&#160;</td>
          <td style="width: 6.48%; vertical-align: top;">&#160;</td>
          <td style="width: 7.27%; vertical-align: top;">&#160;</td>
          <td style="width: 7.39%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: top;">&#160;</td>
          <td style="width: 23.3%; vertical-align: middle;" colspan="3">&#160;</td>
          <td style="width: 6.48%; vertical-align: top;">&#160;</td>
          <td style="width: 7.27%; vertical-align: top;">&#160;</td>
          <td style="width: 7.39%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: middle;">&#160;</td>
          <td style="width: 1.93%; vertical-align: top;" colspan="2">&#160;</td>
          <td style="width: 21.37%; vertical-align: top;">&#160;</td>
          <td style="width: 6.48%; vertical-align: top;">&#160;</td>
          <td style="width: 7.27%; vertical-align: top;">&#160;</td>
          <td style="width: 7.39%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: middle;">&#160;</td>
          <td style="width: 1.93%; vertical-align: top;" colspan="2">&#160;</td>
          <td style="width: 21.37%; vertical-align: top;">&#160;</td>
          <td style="width: 6.48%; vertical-align: top;">&#160;</td>
          <td style="width: 7.27%; vertical-align: top;">&#160;</td>
          <td style="width: 7.39%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: middle;">&#160;</td>
          <td style="width: 1.93%; vertical-align: middle;" colspan="2">&#160;</td>
          <td style="width: 21.37%; vertical-align: middle;">&#160;</td>
          <td style="width: 6.48%; vertical-align: middle;">&#160;</td>
          <td style="width: 7.27%; vertical-align: middle;">&#160;</td>
          <td style="width: 7.39%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: middle;">&#160;</td>
          <td style="width: 1.93%; vertical-align: middle;" colspan="2">&#160;</td>
          <td style="width: 21.37%; vertical-align: middle;">&#160;</td>
          <td style="width: 6.48%; vertical-align: middle;">&#160;</td>
          <td style="width: 7.27%; vertical-align: middle;">&#160;</td>
          <td style="width: 7.39%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: top;">&#160;</td>
          <td style="width: 23.3%; vertical-align: top;" colspan="3">&#160;</td>
          <td style="width: 6.48%; vertical-align: top;">&#160;</td>
          <td style="width: 7.27%; vertical-align: top;">&#160;</td>
          <td style="width: 7.39%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: top;">&#160;</td>
          <td style="width: 23.3%; vertical-align: top;" colspan="3">&#160;</td>
          <td style="width: 6.48%; vertical-align: top;">&#160;</td>
          <td style="width: 7.27%; vertical-align: top;">&#160;</td>
          <td style="width: 7.39%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: top;">&#160;</td>
          <td style="width: 23.3%; vertical-align: top;" colspan="3">&#160;</td>
          <td style="width: 6.48%; vertical-align: top;">&#160;</td>
          <td style="width: 7.27%; vertical-align: top;">&#160;</td>
          <td style="width: 7.39%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 2.11%; vertical-align: top;">&#160;</td>
          <td style="width: 23.3%; vertical-align: top;" colspan="3">&#160;</td>
          <td style="width: 6.48%; vertical-align: top;">&#160;</td>
          <td style="width: 7.27%; vertical-align: top;">&#160;</td>
          <td style="width: 7.39%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 2.29%; vertical-align: top;" colspan="2">&#160;</td>
          <td style="width: 49.22%; vertical-align: top;" colspan="6">&#160;</td>
          <td style="width: 2.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.62%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">EVENT&#160;#</div>
          </td>
          <td style="width: 1.48%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23.8%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.04%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.57%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.29%; vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 49.22%; vertical-align: top;" colspan="6">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.62%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23.8%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.04%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.57%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.29%; vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 49.22%; vertical-align: top;" colspan="6">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.62%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">CLIENT&#160;#</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
          <td style="width: 1.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23.8%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.04%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.57%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.29%; vertical-align: top; background-color: rgb(0, 0, 0); padding-bottom: 2px;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 49.22%; vertical-align: top; padding-bottom: 2px;" colspan="6">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;Authorized Signatures - This section must be</div>
          </td>
          <td style="width: 2.48%; vertical-align: top; background-color: rgb(0, 0, 0); padding-bottom: 2px;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.48%; vertical-align: top; padding-bottom: 2px;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.62%; vertical-align: top; padding-bottom: 2px;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.48%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23.8%; vertical-align: top; padding-bottom: 2px;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.04%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.57%; vertical-align: top; padding-bottom: 2px;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.29%; vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 49.22%; vertical-align: top;" colspan="6">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;completed for your instructions to be executed.</div>
          </td>
          <td style="width: 2.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.62%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23.8%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.04%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.57%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.29%; vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 49.22%; vertical-align: top;" colspan="6">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.62%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.48%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23.8%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.04%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 1.57%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.29%; vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 29.59%; vertical-align: top; border-bottom: #000000 2px solid;" colspan="3">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.27%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.33%; vertical-align: top; border-bottom: #000000 2px solid;" colspan="4">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 39.52%; vertical-align: top;" colspan="5">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.29%; vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 29.59%; vertical-align: top;" colspan="3">
            <div style="text-align: center; line-height: 1.25;">Please Sign Here</div>
          </td>
          <td style="width: 7.27%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.33%; vertical-align: top;" colspan="4">
            <div style="text-align: center; line-height: 1.25;">Please Date Above</div>
          </td>
          <td style="width: 39.52%; vertical-align: top;" colspan="5">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.29%; vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 29.59%; vertical-align: top;" colspan="3">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.27%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.33%; vertical-align: top;" colspan="4">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 39.52%; vertical-align: top;" colspan="5">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.29%; vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 29.59%; vertical-align: top; border-bottom: #000000 2px solid;" colspan="3">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.27%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.33%; vertical-align: top; border-bottom: #000000 2px solid;" colspan="4">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 39.52%; vertical-align: top;" colspan="5">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.29%; vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 29.59%; vertical-align: top;" colspan="3">
            <div style="text-align: center; line-height: 1.25;">Please Sign Here</div>
          </td>
          <td style="width: 7.27%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21.33%; vertical-align: top;" colspan="4">
            <div style="text-align: center; line-height: 1.25;">Please Date Above</div>
          </td>
          <td style="width: 39.52%; vertical-align: top;" colspan="5">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z5dd8f0cc0f8d4b3da6349aec5a839441" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 1.99%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 52.94%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Chemomab Therapeutics Ltd.</div>
            <div style="line-height: 1.25;">&#160;</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Instructions to The Bank of New York Mellon, as Depositary</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">(Must be received prior to 12:00 p.m. EST on October [__], 2021)</div>
          </td>
          <td style="width: 40.06%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.99%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 52.94%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 40.06%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 1.99%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.01%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 52.94%; vertical-align: top;">
            <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The undersigned registered owner of American Depositary Shares hereby requests and instructs The Bank of New York Mellon, as Depositary, to endeavor, in so far as
              practicable, to vote or cause to be voted the amount of Shares or other Deposited Securities represented by such Shares of <font style="font-weight: bold;">Chemomab Therapeutics Ltd. </font>registered in the name of the undersigned on the
              books of the Depositary as of the close of business on <font style="font-weight: bold;">October 1, 2021 </font>at the <font style="font-weight: bold;">Special General Meeting </font>of the Shareholders of <font style="font-weight: bold;">Chemomab



                Therapeutics Ltd. </font>to be held on <font style="font-weight: bold;">October 25, 2021 </font>or any postponement or adjournment thereof in respect of the resolutions specified on the reverse.</div>
            <div style="line-height: 1.25;">&#160;</div>
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">NOTES:</div>
            <div style="text-indent: -9pt; margin-left: 9pt; line-height: 1.25; font-weight: bold;">1. Please direct the Depositary how it is to vote by placing an &#8220;X&#8221; in the appropriate box opposite each agenda item.</div>
          </td>
          <td style="width: 40.06%; vertical-align: middle; text-align: center;">
            <div style="line-height: 1.25;"><img src="sc4.jpg"></div>
          </td>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
  </div>
  <div style="text-align: center;" id="DSPFPageNumberArea">
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image9.jpg
<TEXT>
begin 644 image9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0M!W4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *0D*,FESBLW4KU8(6YII7 DN=0BA_BK*G\201'EQ7$Z[XB$1.#7 :
MIXG;<<&MHPT%<]O_ .$MM .91GZU+!XGM9/^6@_.OFR7Q+)NSN-:&F^)G9U)
M8]:7*@/I>VU**<_*P-7P<C->1>&_$GF.H)]*],L+]9HUYZU$HV&:5%(#D4M0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 5+Z?R82U><>*O$!BB<!J[K7WV6+$>E>&^,+TY<;JU@)LX[
M7O$4C.?F-<O+J;RG)--U.0R/R:I1IGK72D3N6C,66B*\>%Q@T^*$'MQ45S$
MW H:"YU>A^(7CF7#8KV7POXD,_EH6YKYMMYS!("#CFO3_!6IDW40W5FT%SZ0
MT^8RQ DU=K$\/3>9:@D]JVZYI;E+8****0PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"\3<:<^/2OGSQBQ+N
M:^AO$,9DL7 ]*\&\96#AV;'%;4R3R6[8E^:; =QP:L:A'A^F*IQG!KH3)V-J
MW12HJ&\4*<"F07 4 $TRZF#'K3;!E%U^<$>M=WX)4_;HCDUP\2%Y1CGFO2?!
M-@XO(FQ638^A]!^%1_H8SZ5TE8/AR,I:CZ5O5SRW*CL%%%%2,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J7\
M?F0$$5Y?XNT8RQN53BO670.,&L/5],6>!ACK6E-V9+1\JZ_HTJR':E<U):21
M=1S7O'B+PX<DHN:\[U3P_,K'"&MTQ,X;#BI$BDD.*VFT2?=]PUHZ?X?G=AN0
M]?2FP90T;19IIURN17L7A/0I(9(V*8%4O"_AMC,NY/2O6]*T98$4XZ"LI,%J
MS1TJ+RH ,5HTR.,1K@4^L66%%%%( HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.6,2(5J2B@#GKW1%FKG;SP
M>LC$UZ$0#33$IZBKYV)H\M;P*N[=5ZU\'*F#CI7H?D)Z4HB0=!3]H)1.>TS1
MUMW''2NA1 JXI0BCH*=4MW*L%%%%2 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4A(%,>0*.M5IKM%0_,/SJE%L5R=[A$ZFHOML0ZL*Y?4=3VN<-^M8SZ
MRQ)&_P#6NJ.&NC-SL=[]OCW?>&*>+Z(_Q"O.#K+YQN_6GQZR^[&[]:MX1O87
M.STA;J-NC"I5D5NAKA;;5<G[_P"M;MKJ(('S#\ZSGA7%%*9T%%00SJZ]14]<
MK31:84444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !124M( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %12R!!R:>S "L;4[O8IYJX1NR9,@O]05"?F_6N;O=7PQ^?
M]:R-6U<B5AOKE[O4G9R=YKTZ5)6,I2-R^U/>Q^;]:RFNR3P3^=97G/*<@FID
MW&N^E2,7(MFZ;U-.6\*]S4/E_+[U$RD5W1H)B<C6M]2*GEC^=;UGJ?0[_P!:
MXCYEJ:&ZD1A\QQ4U,.F:1=CUG3]2!"_/^M=+:W*RC@UX_8:HP*_.:['2M3+,
M/GKQL3A'N;19W-%5;:Y65!@\U:KR&FG9F@4444@"BBD[T +12&HVE [TTKBN
M2T56^TKTSS4D;Y'6FXM F2T445(PHHHH **** "BBB@ HHHH **3-1M.J]31
M8"6BH1<(>XIWG+ZT[,"2BFAP>].I %%!Z5$22>* ):*1>G-+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]Y(6^\:KDN#9]/:3XV%VX!85V%EJ:W"J0>M?,6@:T874$UZSX<\0AEC!-1*
M'K((9:;MP<UGV5\)8UK24Y&:Q::& Z4M%%2 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM>@Z98F/;\O%1Z=I0B(R*WX8P@ KR,37YGH7%$L:[5I]%%><6%%%% !1110
MC#(K$U6R,J,0O:MRHYD#H1ZTT["9XUK>C%Y&PE>>ZOX><EB(Z^@-0TCS')"]
M:YO4/#FY&(7FME(BUCYTO-(EA?E:CATYY#C;7KFJ>$W=C\E4[+P@X?F,U:D#
MM<Y;1O#DTC ^7Q7I7A_PY(ACS'6QHGASRPH9*[C3]+6)5XZ5$I @TRP,,:C;
MBMM1A:1$"C%/K*3N:!1114@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"10#F@!:*** "BBB@ HHHH
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M=3']X?G3EU($]1^=/V,A<R-6BJBW:D#D5820,.M0XM%#Z***D HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"EJ(/V9R#VKQ;Q=<D%P&(Y/>O:]0_
MX])/I7A/C*-RTFWU- [GF>IWLGGD!SU]:VO#EY)E06)Y]:Y744<7)!]:Z/PP
MN=N>N:M*XCVOPR[M&N2>E>C68/DK7G_A6$^4I([5Z';#$0HF!-1114 %%%%
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MB-]]_H:^?=44"Y?'J:]_^)#XD<>QKY]U-O\ 26^IK5),S>YM^%$'VZ,CUKZ
M\+1DQ(?I7@/A'_C^C/O7T3X44-;J:&([FW_U2_2IJ9%P@I]9,T04444AA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$XH 6BF!
MLFGT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%,+8.* 'T444
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MY%-LK)( "%P:OUDV6-"*.@IU%%2 4444 %%%% "%0:AEM8Y <K4]%%P.<O\
M18Y%/RBN<_X1H>>3M&,UZ(Z!AS5<6J[LXIW YW3M"\IP<<5TT$(B7 %/2,(.
M!3Z+CN%-?[M.I&Z4A'DGQ#C!=\CL:^?]8@V7#'W-?17CT*6?/7!KP#7,><_U
M-;1M8C=D_A24+?QY]:^A/"ER/(7%?/'A9,ZBGIFOH3PI;DP(0*;%U/0X'W1B
MIJ@A79$/I4<U['$#E@*Q99;R*3(K GUV&,D>8*JMXFMUZS+^=%AG4Y%+FN6B
M\2V['_6C\ZL+K\!Y\T46%<Z&BL6/6(9#Q(*TH;E)!P:+#+%%%%( HI"0*6@
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M_ENOYT6 Z_(HR*Y4>*+8])E_.IHO$$+G_6BBP'2T5EP:I$Y^^*N)<HYX.:+
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M-;#,?^RH]V-H_*K\%JD*@ 58P*6FYM@&,4445 !1110 4444 %%%% !1110
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M;(SL!(W_ 'U7+3ZA<7A+!F.?>A1U$=;)XGE9C^]_6FQ>)I=W^L/YUQ8@N6Y
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M:!N/7UKL?&<WG;\'N:X2 'S0/>MT@/=OAC,SE,G/->\0_P"J7Z5\_P#PMX*
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M#T<6,QBMF#3TC& HK0P/2EK*Y21''&$& *?M%+11<92NK-)4(V]:YR^\,Q7
M;,0)/M784F!Z47 \FU#P/%@GR!^5>?>(/#7V7=B( #VKZ3GMEE7H*X3Q/X?\
M]&(6FF2T?-\RR6EUQD &MVSUB1;?;YAZ5JZ_X::*1VV]*X:[D>SD*"NB#1-B
MYJEP;D$9S6+'"1*/K4HN"U+&^91]:Z-&@T/8OA>F"F?6O?(?]4OTKP7X8G+)
MGUKWJ'_5+]*XJNY:)****R&4M2S]DD^E>%>,22TF/4U[OJ'_ !Z2?2O"_&2;
M6D(]36](39Y%J.5N23ZUO>'KT1J,MWK#U53O9N]065Z8>]>A!(@]=M]>\F(?
MO,<5EZQXBDE@9?-)'UKBFUMBH!-26<CZA.(ST-1*P6=S/O3+>7>>2,UJ6&B-
M+CY/TKLM%\$&[*OMS7<Z?X&$0^[7/.PSS[3?"WF8_=?I7:Z9X*5HE)@&?I79
M6'AI8,?+736=DD* 8'%<\F%F>67W@I0I_<#IZ5S-QX/PS?N1^5>^7%HLHZ"L
M>31$<ME:5QI6/G;5_#;01L?+QBN$U"R>&0X&*^G]:\+>=&X"5YAXB\&F(,P0
MU2*L>6V-U) _4BO0/#OBAXI(U\TC'O7%ZAI;VS<"JMI<-;3!L]#6B0CZJ\.:
M]]HACW29S[UVL-PKJ,&OFWPSXI,2QKNKV/PUK?V[ )J)1 [>BF(<H#16(7/G
ME7W&K"G<,4SRL=!4JX''>OMG-GGJ(TK@TUFQ4S$8J+&:WIO0&*C=Z>9<"F=!
M41.6]JTM<![-YE1A<FG$CM3UQ3V0A57 Q2-P:D##&.]-;%24EH)NQ2[N*B:A
M3SS3=AH<Z[AFJS1FKBX8XJ;[*7Z"N><RT8CPMFH_F7BNC;3F9.%YJ#^R)2WW
M*X:E2)>ACJ6I2&'-;8T:4#[AI!I$H/S)7,Y(+&%Y39W4X1%N:W#IS+U7BHS:
MX/3BM:4DF#B9B(35F-<'%63$HZ"HLJ#BO0C:Q!.AQQBGGI4:.N*5I5 ZTY/L
M%B(G!K6TL_.#6*T@S6UI!!937'7V&D=[HW*BNKC_ -6*Y71\;1BNJC_U8KYW
M$_$;P1A>*>=-<>U?-/CABMTRU],^)4,FGN%ZXKYZ\9Z9(T[,5I4-R97/,1PU
M7[-.<U!<0&%_F&*N6+J.M=T4F!?%OE=U9E]%R3Z5NI-'MZUDZE(FX[:<DD@2
M,%CB3\:[_P #,3?Q#_/6N$6(RR_*.]>D>![-A>1?+S7!-ZEL^B_"XQ9CZ5T%
M87AM"EH ?2MVN=[E+8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH #TK%U@_NS6R>E8NL$&,XJD(\,\>',4PKQN9?WY'O7LO
MCLCRIJ\A*;[CIWJQ7U.Y\"0_O1]:^F/#T.S3HS[5\\^!(-D@R*^C=$&-/C^E
M*0T:=%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK\K3J:_W: /
M)_B$/G?Z&OGW65Q._P!37T%\0L[G^AKP#55/VA]WJ:WCL9/<Q$B+/73:!IIE
MN(S[BLW3X \X&*](\,Z7NDC(3N*%L'4]3\'Z8/LB9':N^A@6- ,5D>'K80VB
M#&.*WJRD]31"8%+114C#%-**>HIU% '-Z]8+-"_'8UX=XKT(YD..YKZ+NH1(
MAR*\^\5Z?%]FD.T9YK:#$SYHN(/)G*^AKH_#,Q6X0 ]ZS_$$8CO) !WJQX:E
M43J&ZYI-:D'T/X-F/EUWR'*YKSCP7("E>C1?ZL5FU9E18^H9Y-D9/M4U8VL7
M/DQ-SCBA;E')>*=3Q"PKY[\6SM-?N0>]>F^*M85MZA^YKR'5Y#<7C8.<FNM)
MI$F7# SRCGO7I/A/1S(JG%<GI%@SR+E<\U[GX'T=?)4LG:LYC1N^'-$$91B*
M[V&%8T Q4-I:QQ1C"XQ5NL&QB=!30^32MTJ'G/%("Q1BFKG'-.H 8R J>*Y3
M7M+$T;G'6NNJ&6!)%(85<96 ^<_&&B; [8KS%X#'*>V*^EO&VDJ\3E4XQ7A&
MN:>T,AVKBNA2NA,M>&+TI.JYZ5[GX6U'_1XUS7S=I-P8;O&>AKV#PIJ?$2EJ
MB0DCV^WDWH#4U9NDR>9;J<]JTJP*,S5?]0WTKQ/QVN6<^QKVW4L>4V?2O&?'
MN,R8]#771V$SPFY/^EO]:O6<9D(&*J7&/MC_ %K<T=$>51CFM4R3HM!TW=-&
M,=Z]L\+:6(U!(KC/#&EJQC;97KFD6@BC'&*QJ.Q1?AB5 .*GR *:PQ4>&SGM
M7,]1$P.>U)M![4J=*=2&8VJVBR0-Q7E_BBQ"1/\ +7L4ZB1"*X3Q=9@6LAV]
MJVILAZ'SGKL.QSBN:D!!X-=GXA4+(<UR0&9O:MK BQI]LTDBGWKV+P5INZ-"
M5[BN#\/V2R/&2O&:]U\(V,2P)A1VH:T*1U^E62I"OR]JV%0*.E,@0+&N/2IJ
MY).[*"DXH/2FKD'FI <0".E8^JV:O"QQVK9J&X0-&0:J+LP1X#X[T_$;'':O
M&+N(K.P]Z^DO'UFI@;"]J\"UBW"2L0.]=7031/X<8BZC'O7T'X4FVV\8^E?/
M&A'%W&.^:]\\*/B"/=[5G)#1Z?;-NC7Z58JI9_ZI?I5NL'N R0[4)KC_ !%?
M>6AKJ[N01PL37EGC+5$4<-6E-";/-/&FHF1F&:\X<M--CU-=!XCO?.E8!N]4
M-+M//D7C))KIBR=S:\,::7N%X[U[EX=T8(B-M["N+\':(?.0E.]>VZ98+%"G
MR]JF<DD-%BPMECA Q5[:OI0JA1@4M<C=V4)BEHHI &*3:/2EHH B>-".E<OK
M^G++#(0O:NLZU7N;=9(R",YJX2LP/F;Q7HA^T.0,=:\[O+1H)/3!KZ6\4Z$K
M[V6/L:\.\3Z:T+-A<8)KJ<KDE#1[LQN@S7LG@;4-TB#/>OG^*1X9!R1BO3_
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MT-*![U]$Z*X;3X_I1/8I&E11168PHHHH **** "BBB@ HHHH **** "BBB@
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M"\;)M@/TKP/Q%\K,?>NA/01EZ+A;R//K7NWA1@T4>?:O!])&Z\0^]>X^$O\
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M$<,V?6M>@&1I((O4/;->Y>%!NCC(]J\,THDWB8Z9KW+PCGRH_P *2$>KV/\
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MBBLQA1110 5#.#L/TJ:HI_\ 5GZ4T)GDWQ'4M8MCWKYSO5_TQA[U]&_$5O\
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M%%% !12$X&:B:=!WIV FHJNEU&S8!%3A@>E(!:*** ,W4AF)OI7B_CU%W/\
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MMD*>:W-'T5Y95RAY]J]'TKPFCJA*'/TI,1PGAC0+G[;&S*<Y]*^B_"%K)!"
MX[5D:)X1BB97*X(]J[FRM%MUP!4L"[2,,BEI&.!4@>3_ !#D\MW'L:^?=8E!
MN'QZFO>/B47,KX!^Z:^>]1$K73_*?O'M5IDVN;WA-O\ 3X_K7T/X3?\ <+FO
MG?PM$ZWL9P:]^\*N_DKD47N-*QZ/"?W8J6J]JQ,8S5BH&%%%% !1110!%/\
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MN%7#9S4.%A\QMT4BG(S2U!04444 %%%% !1110 4444 %%%% !1110 4444
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M!4@&*6B@ HHHH **** "BBB@ HHHH A-NA.2*<L*KT%244 ( !2T44 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.*ZZQM_+'2BWLO+ XJ^JA17EUZ[GH6HH=1117(6%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUS4E8E(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU37(YJD+O:VW%.X&Q$ !4E8XU J<8J0:CBD!J45FI?EFZ59CN-YZ4 6:***
M&!CNIQZ4PO@]*KSW.P8H +A5(K$G@7>2*M2W9JKN+/F@":V)3&*UH)F(Y%5K
M6W# -5\1 #B@!/,HI?+HH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "F/&K]13Z* *%Q8QR#E16#>
MZ$LA.(Q76$9I"@/:J4AW.''AX _ZL5<@T(+C]V*ZORE]*4(!5<XC+M-.CB(^
M4"M-(PHX%. Q2U#=Q)6"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
A44 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image10.jpg
<TEXT>
begin 644 image10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0Q!WD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!C>(L_V>_I7SWXL9@9.*^AM>4M9.*\#\5V;$R'FMH$R/*K_ #Y^3UJ!
M#D^]6M1C*3%2>]4QZ9KH3)-:U!V=*;=@A>G%1V]QM6BZG#1TWL!GOC/O76^#
M@_VH'W%<HB;WQZUW7A"U(F4>XK/81]$^#C_H"8].:ZRN8\)0[+!/I73USS>I
M<=@HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@"GJ$(EMV!KROQ-HN^.0A>WI7KSKN7%8&KZ5YT#X7M5QE
M8EGRIXBTEX9V(4]:YIH)%Z]*]Q\2Z"V]SY9Z^E>>:EI+QDXC/Y5T19)R.YDX
MH(DD/&:TWT^0,?D/Y5;L=-D>0#RV_*KE>P%/3=-EEF7Y:]7\):$ZNK,O'':J
M'AW0F>9?W9_*O9= T+R8%8I@5SWL,V]!MS!9(,<8K7J.&/RXPH[5)63=V6%%
M%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ IKH'4@BG44 <QJWA];PDA!^5<E?> S(2?*'Y5ZIBFE >HK15
M&A6/%G^'1))$7Z&K=EX ,1&8A^5>N>2GI2B)1VJG5N+E..TKPN+5U8Q@8]JZ
M^&,1QA< 5)@4M9-W&D%%%%(84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(>E "T4U
M6R<4Z@ HII<#O4$MRB#DBFHMDN21*TRIU-1?;(\]:P]1U18\X85BOK.,D,/S
MKIAAVT3[1';?;8AWH%Y&>]<#_;I)Y/%/BUT[L$UI]4=@YSOEN$/>I0P;I7'V
M^L ]6%;5IJ*N!R*RGAY15RE*YKT5''*L@R*DKG:L4%%%%( HHHH **** "BD
M)QS0#D4 +1110 4E+128"4M%%" ****8!1110 4444 %%%% !1110 4444 %
M%)NYQ2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6@ HHII8 XH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H7[80U?K/U%<J<5I2^(
MF6QP7B"7]R_TKS_DW)Y[UZ%KD.^-ABN%FA$<YXXS7T&'>AA(G4@KCI[TA) J
M,.HXJ0885ZM(BQ$6/6DSN[U(R>E,( Z5TIH0Y?D'6GEMXZXIBX;KT[4XK@9J
M)-(R>PPKCO3,\]:4N,\TPD$\5<7<E(E![9_&I,X6H!C&>U2J05Y_"DT;Q0QX
M_,&<X]JA9&3O5G(4>]310><,XS43DDBU$RR[ =:%D<]R*W8-)$H/R<?2KL?A
MTM_RS_2N"=>,6'*<N6=A5?8V_P"[7</X>V1_ZOGZ5DS::8V/R]/:JI8B+9+1
MFP#"X/YU90#.<TQPJ<=JA\Y0V,\5V*S0MB]OR/2JER<Y&:B:Y [\U \Q8]>:
MB:5BK"!1GK6_H8)E S^-84">8^!WKL-"L=I!*\?2O&Q3-((]!T)"(%^E;E9V
ME1[+=>.U:->%4=Y&RV"BBBLQA1110!3OUW1GZ5Y=XO@/DR<^O->K7*EDKA/%
M%D)(),KQSVK:F1(^:-=0K,W/>L>/ZUW?B'21O<[._I7'7=OY#8Q@UT<UA#48
M9Q4FT$=:I@GMUJ:.7WJU+0 FA^7.:T/#RG[8O-5"1)A>U;_AZRS=)\M9MW&>
MW>$5)@0_2O3K#_4@>U>>^%83'"HQZ5Z)9A1$,=:YIE(LT445F,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ JO<J&4C%6*9(,K3B[,3V.,U>#*M
MQ7":I;['+8KT_48-RMQ7$ZO:-ELKS7N86>AC)6.(WD25:CE 6H;F%ED.!5=2
MR<'I7L4F9V-8.K)32FXU224\<U?B<$#/6NK9707&XV'I3F<;<8SFDN"%&1UJ
MNA+,*RD]3-H4QY/2DV[>U6P 5JO,&']*N$K D0;QG^E68ANX S6>4?S.*VM.
MA<LO%%2HDM#:*N30:<\S  5O6.B. /E-:6BV6]@2O'TKL[>R14'RC\J\+%XY
MQ=C51.?L-("J,QXK=@TZ)5&4%7UC5>@IU>/4Q$IE<IGW-C&R8""N5U'2<[L)
M7<GD56GMU=3D55#$2@R)1/(K_2W5R0F*Q;FQ=<G;BO5M0T\LQ&WGZ5SMYI3<
MC9S]*]ZAC%)*YGR'G@MVSS3DLG>3'/UKJ9-&??\ *G'TJU::,VX93]*VGB(V
M'8Q],TEV<''2O0M&TTI&I*_A4>G:65(^3]*ZFV@\N,#'->-BZR>B-8HG@0)$
MHJ6D'2EKRWN6%%%%( HHHH 1AD5AZS9B6%OEK=J&YC\R(BJB[,31XIKVAAP^
M$KSC6O#LF20IZ]:^B-0TS?G"<_2N4U30BV<1\?2MF[DL^=[C2I8#R#]:C2R=
MAP#7J6N>'I.BQG\JR;7P[,'&Z,Y^E6FK".<TG0IIG4E2>:]$\/\ AQTF0[*V
M="T KM!CY[\5Z'I&CJA'R#\JGF ?H>F&*%05Z=ZZB) B "FQ1"- H%2UC*5V
M4D%%%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4=:** *=Q
M;AE-<OJVG[@U=F1D8K-OK0.IKJH5G%DR1Y1J&G[<\5SEW$R/7IM_IN=VX<?2
MN4U'2L.3CGZ5[U"LK&31RBL5-68YL5-/9%"<=:JB,@UVJKH9M%MI/,%(@P?2
MFQK^52L.F:B4Q6'[^V::?GXZTP8+\=:NVEJ9'^M92JE6((+5I' _6NHTS32Q
M7VJ6QT;(4X_2NMT[2-B@D?3BN*MB[(UBB72;/RL5T Z5!;VXB%6*\2M4YY7-
M$%%%%9#"D(S2T4 026ZR=>M59=+20>]:-%7&I*.PK&,=$0G.14L6D(ASQ6I1
M5.M-]0LBM%:K'TJP!@4M%9N3>XPHHHI %%%% !1110 4444 026RR53GTI).
M:TZ*=Q-7.7N_#$4W.!4$7A")3SBNOQ28%/F%RF/;:%'!C&.*TXX%C VU-12N
MQV"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "F[OFP*=30H% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=3WIX8&DTT%QU%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XOQ5.4CE.>
MQKM*X'QBOR2G)[T >,>(]2D1WPU<S8:M.U^J^8:N>)&+2N 37/Z8-M\O/>G$
M#VCP[>R%%RQZUZEH4K2(I)[5Y+X84,BY]:]<\/Q@1J?85;V Z(=*6BBLP"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ)Y@@)--)L"6BLU]2"9JG+K
M>SZUJJ$V+F1O45S!\2C.,U+'KP;J:?U>8N9'1452MKT3#K5P'(K*47%ZCN+1
M114C"BBB@ HHHH **** "BBB@ HHHH **** "JEW<"(9S3[BX$2$UR>JZP%)
M&36U*DY,5R?4-;6/.'QBN1OM>#NV7S5#5=1,CG!-<U-+(6)!)S[UZ=+"LARN
M:%[>^<QP<YJ@P)%0Q.Q;!Z5I16[R8XXKM5'E1FVS,,;9S@XI=A'(4UU-MHS3
M 949K1A\+._114RK1B*USB5+ 8P:0AW^4@UWW_"'D#A14,OA9HA@J,5,<5&X
M<C.'%M@YVU,@*MTXKJ)=#91]T5FW&GM%S@9KHC5C(%%E:&Z\KK^%:EKK.Q@-
MU<]/N1B,5$N[.<G%<]:S-8GK6DZLD@7YJZNUN%D7@UXOIFK-;LJD_2N_T#5F
MG< FO+JT[FMSM**:C;E!IU<(@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** $8[1DUE:C?I'']X?G4NI7@MK=B37E/B'Q9Y4K
M+N/?O6D8]26S2UW640/EQ[5Y-X@UT&1@'YI=9\3M.Q 8\]>:Y&[D>[;CD5I<
M16O;YK@MU-5((&?'R'\JZ+3/#LEV5)7K7;Z;X#+A3L&?I4@<9I>AO,R?NR<^
MU=E8^$&D4?NOTKO=%\$_9PIV*?7BNQM- $2XV+^5-22&]CR>+P.[#_4_I4Z^
M!S_SP_2O9(].4#&Q>/:I18)U*+GZ57.B;,\9_P"$+9.L/Z53N_![ 8\G]*]R
M;3HR/N+^55+C1T<?<7\J.=#2/GC4/"K1H3Y7/TKDK_1WB8_NSQ[5],WWAD3*
M?D'Y5R&J>"]Y;]VN?I2YD.Q\[R1M#-G:<?2M/3+XQS+G-=WJG@IHV+;!GZ5B
M#PRRS# Z&I<AG;^&-4)**&/:O6]"N]X'/:O)/#NDM&4]B*]7T"T8 %NPIMW0
M'6*<C-+2+]VEK 9P7C< V\P]C7S+XA7%[)]:^F?'#$6TWI@U\S^()/\ 3)/K
M6L"&RMHRC[<A/2OH/P<O^BQG'%?/FB;FU!/K7T;X-B_T..FT(]&T\ 0#Z5<J
MM9J%A%6:R>Y:V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***.E !12 @TM !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI&L QKN8UU%M=I*HYYKQZM%Q9K&:9;HI <TM8%A1110 4444 %%%% !1110
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MR::E[.HX)K%[@>LGQBW4.,_6K=GXP)<?./SKQO\ M"?=R3BI(]5EC8'>:N*
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MZC3O%2N!EQ^=>")?2Q]&.*O1>(9HP!O(Q22$?3NE^(8954%Q^==1!<QR("K
M_C7R]HGBV?SE!E->M>'?$CRL@+YS5\ET/8]/I"P49) JA:WOFQ!L]JR=<U@V
MT1^;&!6;@T4;TE[#&/F=?SKD_$?B"**%BKK^=<!K/C*:-GQ*1CWK@-5\97%T
M&7S"<T)6)N=E>^,")6 <=?6J(\9L&Y<9^M>9S:C.[$[CS4 O)BPY.*T25A7/
M7%\8$C[X_.FKXQ82??'YUY:;V;;G)XJ'^T9@^=QJ+ F>_:/XL$A&]Q^==C::
M\CD#>/SKYALO$$T+@!S7=Z+XFE94S(:TBBDSZ(L[I)DX(S5NO/O#FL-,%RU=
MS;3"1.O-1.-AEBBBBLP"BBB@ HHJ*:0(.30E< DF2-26(&/>N6UK7HH0P5UP
M/>JGBG6C;6[;7Q@>M>)Z[XOE>:1?-/7UK>,$A'0Z_P", '95<8^M<?=^)GD!
MRV:Y2]U22XE)+$YJO$\CN!R<TWY"N:EUJT\KG&:I.]Q-DA3^5;>G:69P,IFN
MNTSPNDH!,0_*I3U&CS1;&XEZHV/I4IT6?;GRVY]J]NL_!<+8)A&?I6J/!4)7
M'DC\JUT'8^=O[,GA;=L;\JFCO+BV/0C\*]TO_!,*QG$(_*N%UKPVL)($0&!Z
M5,F+E.6MO%,T# 9P/QKJ])\8R&5-S\9]:\_U*R>&8X7&#4-O<2PNI&>#63%8
M^HO"WB))U0.XY [UW"7L4B<,.GK7R]X?\1S0!1YA%>H:-XEDF"AI#34;@6?B
M%>".)B*\"U/5O]-:O6O'5^9K<G.?_P!5>&:@Q-ZQQ6Z6A)VWAC5&:>,9[U])
M>%)O,T^,'KC^E?*?A9F%S'CUKZF\&$G38\^G]*RJ(I'4T445@4%<=XI"F.3U
MP:[&N*\6,0DOIS5PW \*\4E09!7%V7_'\-OK75^*)2SR5S6D+NOUSUS70H"9
MZGX8#%%R.]>Q^'3_ *.N[K@5Y=X7A'EK@=Z],TQU@MNN.*<Z>A"WT.BDN(XQ
MEG _&L>^URWC1OG7CWK@_%/B>6UE95D( KSC4/&UPQ8"4YSZUAR6*;/2=9\4
M1HK%7'YUP][XR?>=KCKZUPUYXCN)]V7)S65]LED8\DYIV%<] C\:2F7&ZMBV
M\8MM&7'YUY1ND SS2K?3+_$1BA"N>TP>+2<?.,?6M6T\4C=S(OYUX0NL3QJ#
MN-6(?$4R,/WAINUBEN?4.B^(()D 9US]:Z*.\BD'RL/SKYBTGQ?/$P_>G'UK
MT_PMXE>]90\F<5#11ZL#D4M5[6821*<]JL5FP&L>PIN']:DHIW \FN-0)3&Z
MN;U"<NYYJ:2Y##&:SYD+MUK[6G243SN9LKC).0>*OVLNP#TJD(B#5B,;:W44
MQ&A)F5>#51XBIX/-2HW&*'&>].-UH"=]R!,JW\ZD,V/I4;C%0,QQ6EKAHA[3
MG>/2I/.+< U2Y)J9!CO5."L%Q)W.>M-M[@HW6EDB+]*C\E@<_I6,Z2:*3.EL
M=6,)4DUUUAX@!5<N,_6O-$)4<U=MKORV +\5YU;!QDM31.QZS#K:/_%^M6?[
M73'WA^=>91:NJX&^K@UE,9WUYD\%%,TYV>@C5 3G<,?6F-JNT_>'YUPG]N(!
MG?3&UM/[]8O#),?,=Q+K84?>'YU2FUX%?E;]:XJ;6$88WU3?5!V:M886/8+L
MZ6]ULMU;]:Y^\U+>3EOI6;/?%SP:J-)YG&:]*C142.8DGN"[$9YJH\3-W^M2
M"$GO4R0Y!!/2NRR2$4#;'/M6UIL1& ?PJGY6TY-:^GJ!@UA4O8$=KX>B*[2:
M[:/[@KCM!Y*BNRCX05\YC7[YT0=T1W$P@C+MVKBM=\2^3%)AQC'K73:W)Y5F
M[9Z"O"?%6K[3( ]80A="D]3)\3>*#-*Z[^Y[UY[J&H/<N0&IVJ79EE.">36?
M%&7;FK4 0U$=N<UJ6%TUJP.>*KI"139P4&:OV>@T]#T+P_XF,$Z$R=/>O9-
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M/R3'KS7TMXTY@F&.QYKYN\1)_I<AQT-;0V,YG,%<M[5HZ9;>;.H([U5B7?.
M17;>']%WNK;<Y-5<#TGP-HL;P1[EYP.U>K6>DV\2CY.?I7-^"].$5JG'0"NY
M5=HQ6<WJ4DB-;>-%P!4BJ%&!2T5F4(5!ICPHXP14E%%P,#5](MWMWPG4>E>#
M^,=  ED(7CGM7TC<1"2,BO.O%.AK)'(V.QXK:#T)9\QZC:_9I.G>M_PW=-&%
M /-3^*M.6V9CZ&L_1'&%[<TI(D]W\$WLDA09X[UZO&<H*\<\ R@E..GZU[%"
M<H#C'%9M%1)*1ONTM074GEPDT+<HP=;U$1Q,H/05\^^/=7D-Q( W&3WKT[Q1
MK!5W4'%>'>*[LSW#'W-=4(Z$LYMI)93R>#72^'=+:>5<\Y]JQ;6S:0I@=37J
MW@C0C(R;AGCK2D] N=!X8\-KYB,R]_2O6=,TV&W@4!>WI5+1M%2WB4UT"J%4
M 5SR8T"J%&!1FEJ*20@XQ20R6D(!&#2)]VG4@(FMXW&"*YWQ!H\,]N?DYQQQ
M73U#<Q"6,J1G-5%Z@?/'B'P\JM(=O//:O+[VR^SW3%1C!YKZ>\1Z$K02,%YP
M:\)\2Z6T$[$+WKJ4M"3,T747@G49X^M>Z^$]5+VT>3^M?.B2&"Y!QCVKUCPE
MJI2&,5$@1[W9S^;$OTJW7.^'KSSX5[\"NBKGEN45+['D-FO+_&&/L<N1VKU.
M[_U1XS[5YCXS ^QR\=JZ:.Q+/G/6\?V@_P#O&H;9%<8QS4^M?\?[C'\1I=-0
M/(JX[]:Z!(U=-TYI'4CI7K_A#0HF1&=<].U<CH>D>8J$"O9?"VF"&%"1^%9U
M):%)FQIFE6\0!*<@<<5M*BKP!3 @1>!1N.,5R/4"7@U&8$?J*$8L<$=*EJ=@
M,G4-/B>)OEKSOQ'I$11B5YY[5ZO*@="#7*>(+$-;MA<^];0EW)9\W>([1896
MVC%<G),\6<'BO0O&-N(Y6X[UYY<\L>*WW1'4:LLDQP<FNT\'Z69IT+#DGT]Z
MY_2K%9<$CJ:]8\%Z0 \9QZ4G%V-4]#T+0-!A"(=G/TKM;6SBBC 5:KZ9;".%
M>.U:0&*YIR&($"]!3L44TD@XQ68 T:L.16=?:?%)$WRUITUTW#%5%V8'C'C+
M2$"-\O'/:O"M<M?L]V_'?BOJ'QI8?N"P&<YKP#Q/9 3.2O>NA.Z$<KI<S"[4
M=\U[SX)N6V1CMWKP6R7;=KCUKV[P7+B.,;:EK01[58/N1<=*OUE:4P,*_2M6
ML)%!67JEWY2'Z5IDX%<EXGOA&A XP*J"U \]\9:N?+D /'/>O$M4O'DE;GK7
M=>+-5#O(N>YXKSH@SW'3.377'8BY/IMDUS,">M>K^$M!1PNY<G/I7,>&=&:5
MU^3@CK7MWA'0UC125IR:2!,VM$T.WC@7*=O2NA2SA0<+3X85B0 "I:XY2NRQ
MBQJO04[ S2T5 !3&B1AR*?10!6DLH9%P5K U/1+>16PGS?2NHJ*:%9%/%:0G
M9B/G?QGX?56<JOZ5Y9?V1MI.!@5]->)]"\_<=M>,^+=#^SJS!>F:ZN;01R&F
M7\D#]>_%>J>$=;<M&"WS<8YKQK+02\C-=?X4U,B[C'2H:N!]1Z)=>?&N>N*V
MJXKPOJ"M&@/I791OO7-<\U9@F./2N<UP$*U=&>AKFM<?&X&KH[E'B7C?[DA/
M7FO(YR/-;'K7K/CAMPD ]Z\HE4F8C;WKMYM"=67-+M_.E48X)KTOP[H"R2(2
MOZ5R7A:P,UU'\O<5[UX8T%2BG;VK*<K!8U="T.%+=?DY^E=5;VD4:@!>12VM
MHMN@458QBN:=2Y5A<8I" :6FLQ7M60#'MXY#EA7,^(]+A:%B%[>E=0KDGI5#
M58/.BQ[5<=]0/FKQ7I"BYD=5Z$]J\^NX&1CZ5[[XIT?+.VSC)KR'6;-8F:NN
M&Q)S<4LBR  UU.B6YNI%W<G-<NJ9N  *]'\&V!F=1M[]:I[:@>A^%=$A,<>4
M_2O4;/3+>*)<)TKGO#NF^5"A(Q@=*[%>%KCDQV&B)!VZ4[ I:*S&)@56N;2.
M5#N6K5(1D4TP/+?%FB1N7(7]*\2\0Z8())..F>U?46M:>LT+$C->$^-+ 1&;
MY?7FNJFKZDL\EC8QS\=C7I?@&Z;[6F3QQ7G$JA9S]:[OP'*%O4R.XXK=K0#Z
M:T:4M:)GTK5KG]"N UJF*WD.1FN&HK,:'4USA>:=4-Q($C)K-#//?'FH-!;-
M@\8/>OG[7]1>>1PQ[^M>Q?$:^Q$_'8U\_P"H73/<.,?Q&MX*PF1P1&>;:.N:
M[WPUH.XHQ'Z5S/AFT^TWJC;G)'->\^&/#86&-BO:MF]!'5^%M%MTLXV9.?I7
M6QQ)&,*,57T^W%O;JH&,5;KEE*[&EH%%%%0,**** "BBB@ IDL2R(013Z* .
M(\1:-%,&RO/TKQ;Q5I @23:,?A7TK>6:W"'CFO(_&>B_NI3BMJ>I)\_-&8Y6
M^M(22?:M74[!H;ALC')K*<;6-=M-:$'1>&,BZC^M?4'@_P#Y!T9[X_I7S!X5
M;-P@(SS7U!X0_P"0;']/Z5A7*1TU%%%<985PGC#[DOT-=W7#>+\>5+D=CS6E
M-ZB9X!XC51)(<5Q,Q&_(KM/$9/FR<<5QDIS)TKTH$#5);@5I:?8R23+GO4%C
M!YDG3/->A>'M ,Y0A<].:<]AG8^#=$C:!-R_7BO5['1;:.)2$[>E8OAK1O(M
MDRN,5V2*%0 =A7GU)%)$2VD2=%J545>@IU%8W&%(5!ZTM%(")H$92"*Q=4T:
M&:-B5_2M^HY8_,0BFF!X7XK\.IO8JO//:O)]9THVTC$#IUXKZEUC0EG0Y'XU
MXSXYT+[.'*K6R8,\GM[LPR#T!KT;PAK+"XC!)Z\<UYC.C13'Y>AKI?"EZ4O%
M&WO5*5R&?4WAR_66V&[K@=ZZ#SUKS+PWJC+ ,>U=%_:S^]#I7%S'GKVQ';FJ
MDBE#[UV-SI.V,^OK7-:A;>7QZ5]-"LI['-RF>&([U(C&J;R8/6GQ2YYKJB[D
MV)Y 3R?PJN<D^]61\XQ33#@]:Z(NP<I",@4X9 R.E2&/-'E<=:=T+E9'YA]:
M>')&.]((<9)-."C;Q^=)N**5Q&7CBH\D*?2I6!X&:LP61FZ?E7/4K**&DR*W
MB9R*WK*Q$@&1S4]AHC$K76:?H8102*\VOC(Q6Y<8F5;Z,K ?+^E7X_#$3KG;
MQ]*Z*&Q5.U74C"C%>/5Q<F]#51.4_P"$7B4?='Y5&WAI%[#\J[':*:T885BL
M3,?(>>WFC"+.!S]*QYK';GCBO2KO3A**R9="WUW4L7&VI+B>:W-MY9R!\M9L
MI8-_*O2+SPR2N?TKG;WPZR$FO0HXJ+6Y+1RP9@<D\TOGM@X-6+FS:(D9_&JH
MB(ZFNQ331(&0L.>E;&FGIFL-@0<U?LKG81SFN6N[Z"/3- QN7UKL$^Z*\\\/
MWN67!KO;>4/&.:\#$Q=S6F[#-0@\^V9.QKROQ-X:4QR.1V]*]>.",5B:MIHN
M('&W.16=.5BI(^3O$.FFUNFP.Y[5@K*T;<<&O<O$_@\RR,P3OUKS35O#;VI/
MRX]Z[E5T(V,"._=1@&H[BY>8X[58.F/NQTK4T[P[)<R#@GVK.54I;F;IE@9Y
ME##.?:O6?".@".17 YX[54T'P6WF*2*]7T'P[Y"+GMWKAJ2U+Z:'2:)!Y-F@
M]JU*BMXA#$%]*EJ$4@HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
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MY6<MS1;!1114C"BBB@!&^[7)>(]QBDYYP:ZR3[IKD/$;$02<]C6M+<3/ ?'
M.6^M<;I\S1D<\9KK_&SY9OK7'6$6]P<]^E:R)T/:_AQ,TDD>3]*]UB^X/I7A
M'PWA*RIS7NT(Q&.<\5A,I$E9^L/Y=@[5H5C>(I FF2$GM4QW&> ^,]7>.[D
M/ZUYK=3O=W.6/>NF\:W!;4).:Y" %Y@,]3UKL@2SL]"TT2/'QWKVOPAIHB12
M!QCTKS#PS" 8LU[-X>VK$I'I1.((["!=L0%2U% X:,5(2 ,DUQO<H6D*@]:B
M-P@/)%*)U/>@5R0# Q2TW>OK437* XS19CN3T5&LJMT-29I 9VIP>; P/3%>
M,^,=) WG'TXKVK4) D+'KQ7D_BZZ4I)6\'H2T>%ZM#Y%V/7-=3X;O&4(,]ZY
MOQ!(#<?GS3]'O_+=1GO52&CZ6\%7!>)!GL*[NO+OAU<>?'&=W85ZC7.]QE:\
M)$1(KS#Q@Q-I-D]C7I][_J6KR[Q@I-I-]#731V)9\[:X<7[_ .\:31I3]L4=
MLBDU[_C_ '_WC1HB WJ<_P 0K9B/=?"=MYD,1]J];TF'RXQ7G7@JV_T2'OQ7
MJ5JFR,"L*K*+%-V"G45S##I1110 ULU0U*'?:,.U:!!)ZU!>#-NP]JI,31\W
M^/X-MP^/6O++D-OYZU[1X_M-T[GWKR+48/+DZ_C73"3L18VM"CW;/K7M/@^#
MY8\=,"O'_#J!MG/>O;_"<6(X\>@JW(-ST>U!$(J>HK<8B%2UQ/<T04444@"B
MBB@#F?%(+6V![UX#XNMR9G^M?0'B4;H#^->&>+5'F25T4W9"9YK$GEW8],U[
M#X/)\N/GZ5X__P OG7OTKUKP>^$C&:IL#VW1B#"F>N*V:P]$_P!2G.>!6Y7/
M+<96NI?+C)KRSQGJ;KO&>U>C:O+Y<)(/X5XQXUN2"W.<BMJ<=+B9Y-K]\TET
M_/.3531XVGO(QZM4=XAGO6&>I-=+X;T<F[B/^T*UN0>N>#M$4VJ.1V':O4M*
MM1!$,#BN?\)6 2P3/H*ZZ--@P*QJ25K(I(DHHI",]ZP*%HHHH **** (V?!I
MX.1FD9,FG 8H IWMHL\3<<UY/XYT<>2W'//:O8R,C%<1XPLA- PQZ\UK"703
M1\QZII_E2M@5!HTQAOUV\ 'FNSU_2<.U<9' ;>\SZ&M[71&A[?X6U9E,8)_6
MO6M*N3-;@GGBOG?PU?[9XQN[U[QX8E$EDISG@5G42L.)T)Z5ROB#.6P>*ZH]
M*YG78R=U31W+/#O&?1_QKS9(2]SR>]>G>-HMJN<^M>9POMNL$YYKMTL2>B>#
M;/-S'CKD5[_X?A\J ?2O"?!LH^T1@'N.:]\T7YK=?I7+5>@&KWI:;@YSFG5S
M%!0>:** $  Z4V2,.N#3Z* .)\56.VUD8=>:^=/%+>7*_KFOIKQ9C^SY/I_2
MOE_QAS._;FNNDR##L$\ZX&.E>T?#^P)9#VS7C&D'_25YKZ ^'*!E4]3FM:CT
M&CU.RM?+B3/I5^F1C$:_2GUP/<H****0!1110!5OES;-]*\&\?Y!G].:]\NQ
M_H[?2O!OB"F9)\>_%=- 3/$+ACY[?7BNN\%SL+U!GGBN/N3BX<8[UTOA%B+M
M3]*ZKBT/I#P]='R$&:[6V??$#7FOAR0M&GS8KT:P;, ^E<U=:#1:/2N>UO4&
MMXV&>:Z%ONGZ5PGBJ0@,,_C6$ /*_'FI/.C<]J\B93+<G/K7HGB]RRL,]NM<
M/8P>;<$]>:VB!V/@>P)OD/;<*^DM"LPEG&3_ '17A_@>RQ=(WN.*^@=-3;:1
MC_9%34EH!=Z4445@,**** "BBB@ HHHH **** #M7'>)M/$T$F1G(KL:S=0M
M/.B;//%:4W9B9\W^*=+\F1R>N?2O/+Q?+D(KV[QYIWE%C[UXGJ8_THKG\:[8
MO0SU-CPLV+A,>M?4?@TDZ;&>V/Z5\M^&$Q=1\]Z^H_!H_P")9'SVZ?A6-5Z%
M1.IHHHKD+"N'\7KNAESTP:[BN%\7L?+E'UJX;B9X#XER)''Y5Q1SYW-=GXF_
MUC\UQ9_UF,_C7;&5C,VM'3=,,>M>[^!M+\R"-O8=J\3T* M*IZ<U]$> (L6D
M9/& *52;M<M6.XM8/*C"^E6:**X6[E!1112 **** "BBB@!DJ!T(->:>/-,#
MP.<=1QQ7IIZ5Q_C"'S+9N_%7#<3/F+6-,\IW..>>U5_#JE;\#/0UUNOV@S(/
MKS7'6DPM+W.>AKJA S;/<?#C@0CGCBNB\Q/6O)M*\5""+KCVK3_X34>OZ5T;
M$GMU[9KM^[Q7#ZY9C<W':O49XPT9XKDM9L@V[Y<\5.$KN]F5*)Y3=1;&;CFH
M;=@#@]:Z#4]-?>Q"UB?970]*]ZE51ERER/;VJ?C'M5%2RU)Y_'-=*E<=B8X!
MI>-OO59KA:C:8GH?QIN20[$[.HSFF"1>W2H.7J6&SEED&%.*Y:M:P<I;@C\W
MK^%=)I-CG'R\U!IFDN0,K79Z5INS;E?QKR:^)*L6]/LU7;\O-;B(%7 ID4(0
M5-7DU*G,RXH****R+"BBB@ I-HI:* (I8PPZ5CZA8^8APOUXK<[TA0$<BM:=
M1P9#5SS6_P!%SN.SCZ5@W6F^4.5^G%>P2VD3J<H*YC6-*!!VK7IT,9?1F4HM
M'E=W'LXQS4%N0I_G70ZQIS1@G;7-L#&>F*[.?F(9U6A7:QR#YN*]"TZ^5E'S
M5X[8W11P<8QVKL]'U$KC)[UR5J+D"/386WJ#4A4$$5CZ?J*NBCVK524-7E3@
MXLZ(R1DZCIRRQM\HP?:O//$/AOSL_NLCZ5ZX0&&"*@DLH9/O(#0I@XGS^?"#
M;\F$_P#?-='H7ADQN"8N?I7J_P#9=MWB%2I8P1_=0"ES"C%F#I>E)%CY,?A7
M1Q1K&@ %.6-5Z#%*2%%0]2Q:J37B1DC=S3;R\6*)L&N)U+6]CM\U;TJ+D)L[
M5=1B(^\./>I8[M).AKS&/7B9/O5OZ7JGF,.?PK66&:'<[<'(S2U4M)C(M6ZY
M9*SL,****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L#7H]T
M#?2M^J%_;^;$W&>*: \'\61%7D)%>27\H\\@'G->V^.[8QM+@9KP74,K>-]:
MTZ$6.K\*3[;^/FOISPK< Z>@SQQ7R?X:E87T9]#7TOX/NP;)._ XI-7&>@ Y
M&:6HH7WH#4M9E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <+XS
M'[F8^QKYQ\18-S)]>:^D?&1!MYACL:^;_$?_ !\R<=ZTCL92W,C1F U% .F:
M^C/!NW[''FOG31@#J"G'?I7T3X,;%I'Q5Q%(],M/]4/I5BJUG_J1]*LUC+<T
MCL%%%%(H**** &OC:<UQ_B8@6\GI@UV#_=KC/$G^JD!'8UK3)9\_^-,;CGUK
ME]+ W@^]=1XT'S-QWKE],_A^M7)ZB/;/AX!OC(KVV+[@^E>)?#G)DCKV^/[@
MXQ64BD.KG_% SILF.N#6^:P?$W.F2 #MU_"B&XFSY9\9_P#(0DQ7,6TBQR@]
MJZGQMQ?O7)1Q,YX%=D%H2ST+1M62+82X ^M>B:7XLA@B4>: <>M>&0VEW@%=
MWTJ^JWZ+_%4S869]"6_CB$(/WXS_ +U3R^.;=DP)Q_WU7SKY^HKQEQ[TOVG4
M.F6KGDAGO+^-(=W,XQ_O5*GC2 #F<?\ ?5>!B6^(R2QJ%KK4 <9:I3L2?0Q\
M;PXXG'_?55)?&D(Y$X]_FKP,7-__ 'VI1+?OW:J<BUL>_6_CB+/^O&/]ZKP\
M<PJO,X]OFKYU\S4(^A:C[5J'=FJ.HSWN^\;121L//&?]ZO.?$&OQSA\2 YZ\
MUP[2Z@W&YOK5>6WNY1\VZM$]!,KZI<QRRY!!JK8R[9UYXS4LFEW!.2AJ6UTB
M?S5.T]:&QH]V^&-T$2/GL*]FBE$BCFO#?A[:30B/(/:O:+$MM&16;&37>/+.
M>E>9^,O^/.;'3%>F7G,1KS+QB"+*7Z5O2V$SYPU[_C_?_>-&@_\ (03_ 'A1
MKW_'^_\ O&DT+_C_ $_WA6C8CZ8\$;?L<./05Z8F-@Q7F/@7/V.'CM7IR?<'
M&*PJC0ZBBBL1A1110 5#<_ZAJFJ&Y_U#4 SQ'QX0)),?C7C>JD%SZ9KU_P >
MD^>_'>O'M7^\<"NB]D0D;WAO *?6O=_">WRH_7 KP?PSSLR.]>[>$^88QCL.
M:=]!H]$B_P!6*?4</^K%25S,H**** "BBB@#G/$G$!)]Z\,\6C,DAKW/Q'_J
M3^->&>+SB23 ZUM%Z SS/(%YQUS7K/@_!2,_G7DX(^V\CO7K/@XC;'Q1U$>V
M:'CR$QTQ6Y6)HG^I3C'%;1Z5$]QF!X@?; <=:\/\83;F;GG'->T>)-WD-C\Z
M\,\5AB[Y&.*WI[$-GG:X-\?3->B>%POVB+/K7G<(/VT\?Q5Z+X8C;[1$<9Y%
M)Z >_>'0HL5]<"MO-8WAT8T]<CL*UV'I7/(H?12 \4M(84444 %%%% !1110
M 5SOB"-6A.:Z*L'7CB(FJCN)GC?B.%%+DCM7E>HS+'>-SWKU?Q0X^?C/%>,Z
MR3]M;ZFNN,M"&CI/#]X/MD>&_BKZ.\$R%[!>>PKY9T#?]MBQQ\PKZ?\  .?[
M-3/H*SJ,:.Y/W:Y[62"&SUKH3]VN<UI2=V*SI;E,\4\=L ),=>:\I4C[0<>M
M>I^.^$<8]>:\HR?M/3O6[8CTCP2W^EQCMD5]%:%_Q[+]*^<_!)/VN,X[CBOH
MK0,_9A]*QJ#1LT445B,**** "@]**#TH Y;Q80+&3TQ_2OF'QA_KWSZU].^+
MO^/"0^W3\*^8?%O,[Y]:Z*<M"&8ND)FZ7UKZ%^&B<+Z__6KY_P!&XN%'7WKZ
M%^&AX Q_G%:5):#1ZNOW1]*6D7[HI:XR@HHHH **** (+K'V=OI7AGC_ &[I
M_7FO<[O_ (]V^E>&>/\ '[_CUKHHL3/#;P*)W^M;_A3'VM1VXK O2//;CO70
M^$V'VQ3CTXKH3U)L>Z^'0/+2O2=.'^C@GTKSCPVP\M>.]>CZ=Q /I65?8:+C
M?</TK@?%8'S =*[YONGZ5Q/BA0=QQ7-%V&SPKQ: -P/I7,Z&F93]:ZOQD!\Q
MQVKF/#__ !\\CC-:*5Q7/6_!D"^<AQSD5[59@"W3'I7D/A!@9(P%[CFO8;4Y
M@3CL*F;*)J***S **** "BBB@ HHHH **** "HY?N'Z5)5:X8[&^E5%:B9Y3
M\1]OEMZ9KY[U4C[:WI7OOQ'<[&XKY^U0DWK<5VQ=D9V-WPN0;A,]<U]1>#?^
M09']/Z5\O>%1_I$8QGFOJ+P>-NF1CV_I7/5926IT]%%%8%A7$>+E!CEQUP:[
M>N)\6\12_0U4=Q,^>_$X'G2#WYKD8X@\^T"NS\3D;WXYKF=)17U%0WK6RD2=
MCX:TUF*97C/I7O?A"V\FV3C' KSOPK:1E%^4=:]=T6)8[90!VHJ/09K4445S
ME!1110 4444 %%%% !7-^)4#P$ =JZ2LK5H@\+<9XK2GN)G@OB2TVB1L<<UY
M/>L$NF^O%>[^*[;]U*=O8\5X7JT16[?CO7='0SW(EN6 Z\TOVN3^\?SJH!@4
MN/>M+"L^A]XMTK,O+0R@X%:>:1E!KS(3Y7=&K.'OM))+<?I7,WNE,A.%X^E>
MK2VBR')K.N]'CD!X%>C2QMM&+E/(9+-USQ5*6"1><5ZE/X=4@\5DS^'E^[^M
M>A3QD>XN0\V99=Q 'UJ6.&4CD<5W(\.+NZ5<A\,J2./PJIXM"Y3B;.RF>5<K
MQVKL=*T=GP2O/TKH[3PU&H!(%;-MIJP<"O-K8N^B&HE.PTI8UY'Z5L10+&.*
MD50HQ3J\^=1R*L@I***P;*"EI*6FA!1115 %%%% !1110 54N;82(>*MFD(X
MIQDTR9*YPFOZ:VPX6O/-0M6C<Y%>V:C9^=&>,^U>>ZYI9#'BO4P];FT,)1.$
MB)5\FMVUO-@7!K-N+1HW/UJMYQC.,XKTH6:%RGH>F:N%VC/'UKJ[/4T?'/ZU
MXS#J31L.:UK;7G5A\]95L(I[%)V/:8KF-P #4P8'O7F.G^(6R 9,UT=GK0D.
M"]>94P,XFBF=6"#06"]:Q#J:]0U4KS6-BDAZQ6&FV7='2M,BCDUGWFH(J\'F
MN,N_$3*" ^:Q+CQ"S<%_QKKI8"5[L5T=-JNK;4;G]:\_U342S,0>*FNM2,ZG
MYJP+@/(3_*NU45!$CH]1?S0!_.NT\.7+O(N1S7#VUDQE4UW7AVU(=>?QK.;5
M@N>DZ:S;!Q]:U*R].0A!6IVKQZWQ%H****R&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4V0;D8>U.I#TH \G\?VN/-X[5\XZO"4O'/;-?57C2
MS^T!_I7SQXDTKRKB1L>O%:HDP]!E"7B9]:^@/!^H*L*C/IWKYSMG\BY!'8UZ
M5X5UME=4W>E/H(^E-.E66$$'M5ZN8\)WHN+09;M73UD]RD%%%%(84444 %%%
M% !1110 4444 %%%% !1110 4444 <-XSSY$WI@U\X>(W_TF0>_%?1WC+_4S
M<]C7S=XD0BZD.<\UK'8SEN9NC9_M%,^M?1/@T9M8\5\ZZ+SJ"#/>OHWP:,6<
M?-4@DM#TFTXA'TJQ5>T_U0^E6*QEN7'8****0PHHHH 1ONUQ_B12893WVFNO
M?[M<?XE8B"3Z&M*8K'S]XSSN;'K7+:9_#]:ZGQGRS<]ZY#3V(<?6M'N(]R^'
M1 :.O;8SE!]*\-^'!^>.O<HON#Z5E($/K"\29_LR3TK=K$\2+G39.>W3\*47
MJ-JY\K^-L_VD^?6LW2K9964]ZT?&N1J<GUK,T>3$BC=^-=\):$,] TK0A-M^
M7K[5O/X2S&"%_2K'A9%?RLM7IUOIB20KQVJ9M!<\;E\*G^Y^E1#PL^<E/TKV
M[^P(CR0*0^'8L]!7-*291XL/"[!>$Y^E57\+GGY?TKW3_A'HL8P*C;PS"W/%
M0FKA8\,7PNQXV\?2KD'A4YY7Z<5[,/#$(]*E7P[$O855T!XU)X48?P<_2JK>
M%&SPOZ5[DV@1MQQ4?_"-Q>U+F0SQ,>%CC&WCZ4I\*OC.S]*]K_X1N+KQ2_\
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MW6Z'_9KYJ\!ZANO$!;N*^C=(D\RSC.?X13FBC1HHHK(!O.[VI12T4@"BBBF
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M4,1W,FF>9RKLDJ>+&>#S72W>AA&^X:S7L=F?EQBO4IUDR;,;;W(B/6M&+7!
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MXJY6;5B@HHHI %%%% !29&<4M)@9H 6BBB@ HHI"<#- "T5#]H7=BI%;=3L
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MQ\?Q"M; ?2G@;'V.'Z"O38\;!BO,_!&#90X'85Z7%]P5SU=RA]%%%8@%%%%
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M78J<C->*^#_$&VW2/(Z"O5](O?M,(K*2L5$U****@H**** "BBB@!"0#2TF
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MS+7<>)I-TLF#7#2J6EQ7=".A!-;3-&PVUV_A_7&@9 7(_&N#1'4]#5RUF9)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX>T'[.!N1?RK:L=$2(9QQ6S# L0P!4-H+!% D:C"C\JFHHK.Y04444 %%%%
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M@9 T&W!)V"IDTF%.BBM&BB[ @6UC4#"CBI@H P!2T4K@%%%% !1110 4444
M%-9<FG44 5Y+5).H%1#3H@#P.:NT4 5X;5(A@"K%%% "9YQ2TTKSD=:4=.:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 POAL&E4DTUH]QIR@CK3 =1112 **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP*.=HX^E8UQ;.*]>GB="%V%:Z4=Z8)U)SFJ;P-G!ZTU+:7=@5;KJP6-&/#G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** $(!ZTUHD;J*?11<"L]E$W\(JK)I<3=$%:=%6
MJDD*R,7^QXNNP4JZ+$#]T5L8%+5^VF+E,Z/3(D.-HJRMI$O115BBH=23ZC44
MAHC5>@IU%%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ****5P"BBBF 4444 %%%% !1110 4444 %%%% !1
M110 44$XJG=7J01LV>@II-@6BZCO5:>Y5?XJX76?&\=F[*'X!]17*WGQ&7_G
MKQ]16\*+W)<CUM;X9Y:K45TC<[A7AH^(J'K+^HJW;_$91C][^HJY42>8]O$B
MGH:=7F.E^.X[A@/,_45V^FZO'=1@AJPE3L6G<UZ*12&&12UF,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:IJP%@=*6D P*6LP"BBB@")WYQ3D;(JI<S;6]JFM7WKF@"Q3'; I]1RYV<4
M,$V&QUJ8'(S6>2=_M5R-_E&:8$M%%%( K,OV&TXXK3K%U+=M:@"E#.1)G-:L
M$Y;%<]"Y\SWK:LF.1ZT[$W9K(..:?2+]T4M(H*9(P YI]5+EN<#K0 TR9.!4
M\/8504G=5V GB@6Q8HHHH&%5KB3 P*DDDQTJA/*<XII";*UPW/%5\%JG9&<]
M*GBML]N:=K"(HE(Q6C W.*8(,=!S4T28I#18HHHI#"H)Y=HQ4YZ5G7KE5.*!
M,HW,OS]:AC;<]1N2?I4]LI9AD4B30@'0XK17I5:&,@@XJU312"BBB@84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 )12T5*B!@^)Y"FG2'V_I7S9XJN6,TG7K7TMXCB$FGN.^/Z5\[>*;'][(
M0.]:PT(DKGG\AW-SUIF-M.NAY<I':F0D2-@]*[J<TC)P8_YB>.E2J@(YI1&
M:CG;8>.M;.JF@2L(Z[.173^$KAC<A<G@BN7C)D..N>M=MX3T\"16^E<=65RC
MZ"\(R9L8QGM76#I7(>%$VVJ ^E=>O2N:1I$6BBBI*"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ IC)GI3Z* *S0\Y[4Y8@1Q3G.&
MI4P3GO0 Y%VBG444 %-8X%.I#TH SYWSD9JG&2KX)JU=(!N*_C6?&^Y\$G%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK'BCW=.M:D,+;10!=$@)IVX>HJ#RCMQ2>0?4T 6:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"6W65
M2".M3T47 YR]T"*7)*\US&H^%5<G:O->D,H88J)K9&'(%7S: DCR9?"9!^[^
ME7[/PLJL/D/Y5Z(=.B+9VBGK91J<A134R6CF;#P^$89%=+;6:0( !S4R0JG2
MI:3D"0#I1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG4A&: $V"E Q2T4 %5;N 21\=:M4C+N&* ,NTMV#?C6H!@4T1@'BGT %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #2H)S3NE%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4A&1S2T4 (!@<4M%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(,Y.:6B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>sc2.jpg
<TEXT>
begin 644 sc2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" !9 -T# 2(  A$! Q$!_\0
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MBGT+ 4GVF#_GM'_WV*\GN=!TG5O'/BF75-.MKN1+V)$:9-Q5?L\9P/;-2?\
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M?!_C1_Q5'_0G77_@?!_C0!=S1FJ7_%4?]"==?^!\'^-'_%4?]"==?^!\'^-
M%W-&:I?\51_T)UU_X'P?XT?\51_T)UU_X'P?_%4 5/%W_(DZW_UX3?\ H!KT
MS3/^03:?]<$_]!%>8:W8>*]5\/ZAI\7A&XC>ZMGA5FOX"%+*1D_-TYKU*QB:
M'3[>*08=(E5A[@4AD]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>sc3.jpg
<TEXT>
begin 644 sc3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1"  J &4# 2(  A$! Q$!_\0
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@5UZ'&<?G5^B@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>sc4.jpg
<TEXT>
begin 644 sc4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" #G %@# 2(  A$! Q$!_\0
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M444 %%%% !1110 5BZ_>6VFS6=[/I=]?S1LPB-E 96CR.21D<$5M5F:MK/\
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M1P[C_JP" 1CN"!SGBN,UR^T[3];N--74[V73)-36>XM[72S*5N"X?9Y^<#+
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>sc.jpg
<TEXT>
begin 644 sc.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  <%!08%! <&!08(!P<("A$+"@D)
M"A4/$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_
MVP!# 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" ); !<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z1JM;ZC:7
M=U/;6UPDLMN0)54YV'T-5O$4.IW'AV]BT*=;?4'B(@D<9"M7#>#+;7?[,>VT
M^^MK2X@;;>12VPW^;W8GOGKGWH ]+HJ. 2K;H)V#2@?,5& 310!)5&]O;73&
MBEE3#7,R0AD3)+,<#..U0>(])36-%F@?SMRJ7C$,[1$L!P,J0<5Y3IMM8(^B
MQ:?J6K3^((]00W5K)=2ML0/\V]2<;0._<4 >UT444 4=8U"#3M,EEN+VWL2R
ME8YKAPJ!\<=?>O&=(U1Y/%\-M97;B^EN8&GF:\1ED/F'?@YY#+C"_A7L6O1V
M<^E20WQ@'F@K$9U# /@X.#7E6G?V?,^C:':Z-#;:A9ZBDLE\2OEMA\DJV<DM
MZ8]J.H=#V<=**** *]];6]S;,+I(V5 6#2*&"''7FO,]%OD3Q1!;6NCZ?KD)
MN<?VA9V@0VQSG<[D8)&>WI7IFH&1=-N6A*"01,4+_=!P<9]J\ETG8UQI3:4V
MK?VZ;U#=EU?R6BW?/SC:5QTP:!]#V*BBB@1#>-$MC.UPVR(1L78]EQR:\HT6
M6XTS4+&9;G7HM%FO5CMY)'0I(6?@%<9"$GCGI7K4T2SP21/RLBE3QV-<)_PK
M6%EA@7Q)J/EVT_GPQ;U(C<'(_+L* Z'?456TZU>RT^&WEN9+IXUP9I,;G]SB
MB@"2Z69[.9;9PDS1L(V(X5L<'\Z\7TE;Y_&RZ;:1R1Z@MQ#+=RO>(Q.UR9&P
M#G#+CC'2O9[V-YK">*)BLCQLJL#R"1P:\:5=1/V#2]/TC2_[1L+U9GG2_P 2
MR;7R1G;R6[C- 'M=%5=-FNKC3H9=0MQ;7#*#)"'W;#Z9HH KZ_J%EI^CSOJ-
M]'81R(8Q.[8"L1P:\FTF_P!/O[C1]&MHM*AGMK^.7^THKE2T^'SP!\Q9N]>R
M7T;26,PB1'EV,8Q(,C=CC/XUX_I3ZI_PE$5O;KJANQ<PM,)HB(5^<^;@XV[=
MN,8- 'LXHHHH CN-HMI?,!*;#N [C%>1>'_%$K^+K>WT._GM=+DNC$UOJ.YR
MWS<B,!<#)SR6->MW<(N;*:!\;9(V0Y/&",5YOX9U:[L[Z#25UWP[/;6UP(2B
M0R"7EN$!SC=VSZT >G4444 17,"W5I-;N2%E0H2IP0",5YU9_#W5U\0Q_:KZ
MS_LNW>%HVB0B9O+<L 1C'?!.:]%NA,UG,+4A9S&PC+= V./UKQ[3%U=/%:01
M0:A%=-=0-<SSRKL8ASYF.>A7&!B@#V:BBB@#*\27EY9:+,^G6;7<S H%641E
M,C[V3QQ7GOA^Q>UN].DU/PQ*)C<KF^;5 X+%N&QW^E>D:UI,.N:/<:==/+'%
M.NUFA<JP'L:X_2_"G@_3;NRMDUB2>>TF4Q02WVX>8#D?+ZYH'T._HHHH$9^M
MWEO::;(MU,8?M"F)&4'.X@XZ XKRKPOK-G;ZOI^F2:/I+RI=>6+I9I#(3O/S
M8,?+?CUKV*4HL9>7:%4;B6Z#WKE[;QMX>NM1BMK6.:1Y)?+25;<["V<9W>F>
M] '5T444 5]0$1TVY%R0L/E-YA(R N#G]*\H\/ZCXCTZ\TYI[B2/PY)=+#;S
M/9Q9<%L*#@Y"GH#7INNZA'IVF/+<6[3P-E90" %4CDG/:O+=.NK#^U=-AE?5
MY=,-^GV2WEEC,*N7^4\<D ]!1U ]DHHHH H:WIUOJVBW5E=Q+-%+&048$@^G
M3WKS#P?J/A&+5+/2)- DAUJVF"!5@+*AW':^3T]?:O6+N)Y[*>&*0Q/)&RK(
M.JDC&:\CL&CO;W2O#L5E907FGZ@L\FH+<QD2[7RVT [BS#J".M =#V*BBB@"
M&]A-Q8SPJ2#)&R @X(R,=>U>8'PQXL33=/LX= T=6L;M;@7*7.UY0KY )VY!
M(ZG->GW<_P!ELI[@J7$4;/M7J<#.*\VB^(&M76I:>\*V9LVFBBN%0$L6D<@(
M#_>5=I/N:.H'H]A)=RV,3ZA D%R5_>1QOO53[' S15BB@#/UFWCFL3)-=3VT
M=OF5VA<J2 #D''4>U>:^'M),FM6E[8Z1KRVCW7G).]X@B(+??*;LX([8Z5W?
MC6RO+[PO<IIHG>Y4;DC@E$9<^F2#Q7GWAKPYXKMY-((M;ZRC2X22=)KX,@3=
MEQMV]^>,T=0/8**** ,_7=0N-+T6YO+*SDO9XDRD$?WG-<MIOC37M1_L^-O#
M4MK+<2H)FG< (F<,0.N<5V5\)&T^X$#^7(8F"/C.TXX->':=.MYX@TQ;R.X@
MOH;Z*""297(PLA9W!/=RQ&/3%'4#WBBBB@"EJEZ]E;!HK:>X9VV 0H&V\=2,
MCBO+KZ\\2WNI6XU2QOY;2TO$N MMI*HS;&R!N\P\?A7K5Q,EM;23S'$<2%V/
MH ,FN6T[QC?ZG=6YMO#EW]BN),+=,P "YQO(ZX[T =#I.IPZQI4%_;+(D<R[
M@LJ[67V(]:*N 8'%% $%ZI:PN%7 )C8#/3I7D_A.YTZ+4+*&:;7[>Z%T4\CS
MW: G><''3:?2O6KEE2UE9\;0A)W' Z>M>4MI$MQJNF7%MX?LM-1=1BE%[]N+
M;EW] .Y;TH6X^AZW1110(S?$-A;:EX?O+:_29[=HB76%RKL ,X!'/:O'-#@L
M].U;3V%I#)!'=6YAA%W*[('D*C*EB-RD9/%>XW$9EM98U)!="H(.,9'K7GGA
M_P )ZUI>M0W5UHFAR.)3YE\KOYY3/7I@G% 'H]%%% &9X@.HIH\TNDW,=O/$
MID+20^;D 9( R.:X:U\1^*(K'2-2O-:TN>&]O8X'M8K;#[6?& =WW@.O'%>C
MW<K06<TJ(9&CC9@@_B('2O*?#T*7_B"UU47/AV)I;C<;95D,B'=@A06VA_?'
M6CJ'0];HHHH @O3*+"X-N@DE\IMB'HS8X%>*K:W,'B#2Y9KDI+)>P2"W2P$)
M8F4AU#=3MQR>XP:]MGG2VMI)YCB.-"['T &37*6?BU]6U"U:+POJ#V[R8BO7
MC3:BGC?UR!1U#H=?1110!!>O%'87#W)Q"L;&0XS\N.?TKR?1X)M/NM-U%[?4
MK?1Y[U5@<WP;.Y_EW)_=)[=A7I7B*\EL=)>=39K"O^O-XY5 F.>@/->6:5#Y
M>LZ;+)J>E3Z4]\AMK1-1E?:Q?Y2J;<9!Z \"CJ![11110!1UFTBOM%NX+BU6
M\1HF_</TD.,@?G7C%@MQI^JZ3'#/8P1_:X"L$-B5D"M*5:,,Q[$')Q7N%RH>
MTE5FVAD())QCCUKR;0=8U"/6M.LKN\L[JSCNV2"]N-/D^;+?<24MC=V!]J%N
M/H>O4444",3Q7JJ:3HDDMQ8W%W:N&CN/LXRR(5/..IYP./6O-M$U%M;;1]*F
MN+F/3(+N.:!&TZ196VME4=MNT >N:]?NT62SF20@(T;!B3@ 8KR_PWXDU.VU
M"'3?[;M9;&&Z6(-)9L&=6<A5#;O^ @X[4=0/5:*** (+X0-I]P+S_CW,3>;G
M^[CG]*\=L+)_^$@L;S4#J T"2ZABLI6"?,RN3&& &0N3P?2O9IXEGMY(G^[(
MI4_0C%<+)\,HI(HK<>(=4$,$PFBB$YQ&P.1QGL:.H'>CI15;3K1K'3H;:2XE
MN6B4*993EG]R:* )+M96LYEMW$<IC8(YZ*V.#7B6DW,@\9Q6,/VB*]%U 9KE
MY]T<K"0^9@Y_B7 QCVKUGQ7)>Q>'KAM/DMHF*$2/<DA50C!.0>M<#X>$VGII
M32#PW- ]PB)/%&3*VYN"#G[WOZT=0/5Z*** ,OQ&ND/H%T/$?D?V=LS-YY&W
M%<AI%S\,+0Z=/I']D^?),D5J(L&7>QPOR]1SWKN-6CBETBZ6XM5NT$3$P,,B
M3 SBO'].U.^LM4TQ?^)';6LES 8X(;$"54>0J5#$YR"""<4 >UT444 -=]D;
M.03M!. ,DUS&G7WA+6[]#%!9B^LW++'/"$EA;/7!&0<\U>\6:Q/HFBM<VCV:
M2EMJF\F$: X]37E=A&VO^(+)_$U[H^JW$D^P"+4%41@G^",'EAZ]: /;^M%4
MM(T]M+TN&S>YENC$-HEE.6(]S10!)J%I:WEE)'?1)+%@DAT#8]\&O)1!H4.O
MZ;_PCFKWE]>+J$>^V: !0F[YCG8, ?6O2?%6DR:KI!%OJDVERV^94N(C@+\I
M!W#N,$UY[X=UR_M[NRMK_P 0ZD\<<T2%I+50EP&;"G)&=I/&: Z'KE%%% $-
MXGF6,Z%%?=&PVL,@\=#7CF@VVGMX@MI=9&K0$W21Q6DL3"%65R8\.1]W)R!7
ML=W')-93Q02>5(\;*CC^$D<&O'QX.N+77M)D73/.NGNXI&N4NS(%9)"9&8$C
M&5P< 'DFCJ'0]FHHHH ANXGGLIHHI/+DDC95?^Z2.#7G-IH>NLNDZ4VB_97T
MZ]6=]2%T#O7?ER.Y+#M7H]R\D5I+)!'YDJH2B9QN..!7D^G^--:;Q,EI_:?V
MJXDN81+8_9\-$K.5=<=<*!][\: /7:*** ,SQ%%=2^'KQ;"]2PF\HD7#IN$8
M[G'TKR#1M8U-M9TN*[EOIE^UPJ]Y_9Z1><"V%)DWDE3].17M=ZADL)T"JQ:-
M@%89!XZ$5Y1IEK:ZAJ6E17MKX@LIX)T1XA9-]G?9(63+MT7G\J.H^AZ]10**
M!$-X)S8SBT($_EMY1;H&QQ^M>._9=2MO$&EFZN=;GN9KN!VA:<M$&$A$F0.
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>F4#A@.Q]17H5% $<$(M[=(D)*H, L<FBI** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
